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Abstract 
 
In the last decade, induced pluripotent stem (iPS) cells have revolutionized the utility of human in vitro models 
of neurological disease. The iPS-derived and differentiated cells allow researchers to study the impact of a 
distinct cell type in health and disease as well as performing therapeutic drug screens on a human genetic 
background. In particular, clinical trials for Alzheimer’s disease (AD) have been often failing. Two of the 
potential reasons are first, the species gap involved in proceeding from initial discoveries in rodent models to 
human studies, and second, an unsatisfying patient stratification, meaning subgrouping patients based on the 
disease severity due to the lack of phenotypic and genetic markers. iPS cells overcome this obstacles and will  
improve our understanding of disease subtypes in AD. They allow researchers conducting in depth 
characterization of neural cells from both familial and sporadic AD patients as well as preclinical screens on 
human cells.  
 
In this review, we briefly outline the status quo of iPS cell research in neurological diseases along with the 
general advantages and pitfalls of these models. We summarize how genome-editing techniques such as 
CRISPR/Cas will allow researchers to reduce the problem of genomic variability inherent to human studies, 
followed by recent iPS cell studies relevant to AD. We then focus on current techniques for the differentiation of 
iPS cells into neural cell types that are relevant to AD research. Finally, we discuss how the generation of 
three-dimensional cell culture systems will be important for understanding AD phenotypes in a complex cellular 
milieu, and how both two- and three-dimensional iPS cell models can provide platforms for drug discovery and 
translational studies into the treatment of AD.   
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Introduction 
 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder associated with severe memory 
impairments and has become the 6th leading cause of death in the United States (www.alz.org). The first case 
of AD was published in 1907 by Dr. Aloysius “Alois” Alzheimer, who described a 51-year-old woman with 
serious memory loss. Post-mortem analysis of her brain showed severe brain atrophy and neuronal loss, as 
well as the presence of dense extracellular deposits and intracellular aggregates within neurons (Alzheimer, 
1911; Graeber, et al., 1997). These features were eventually identified as amyloid plaques and neurofibrillary 
tangles, respectively (Glenner and Wong, 1984; Grundke-Iqbal, et al., 1986; Kosik, et al., 1986), and the 
condition became known as Alzheimer’s Disease (Kraepelin, 1910).  
 
Amyloid plaques are extracellular accumulations of -amyloid (A) peptides that are derived from the 
proteolytic processing of the -amyloid precursor protein (APP) (Goldgaber, et al., 1987; Kang, et al., 1987; 
Robakis, et al., 1987; Tanzi, et al., 1987). The -secretase complex cleaves APP at different positions, 
generating different size amyloidogenic peptides Aβ43, Aβ42, Aβ40, Aβ38, and Aβ37 (De Strooper, 2010). Of 
these, Aβ40 is the most abundant in both healthy and AD brain tissue, whereas the Aβ42 variant has been 
shown to be likely the most deleterious (Jarrett, et al., 1993; Portelius, et al., 2010). Much of our 
understanding of the mechanisms underlying AD pathology comes from a small population of individuals with 
early-onset familial AD (fAD). These cases harbor causal mutations involving primarily the A processing 
enzymes, presenilin 1 and 2 (PSEN1, PSEN2), which are part of the -secretase complex (Levy-Lahad, et al., 
1995; Levy-Lahad, et al., 1995; Rogaev, et al., 1995; Schellenberg, et al., 1993), or mutations within or 
duplications of the APP gene itself (Goate, et al., 1991; Goate, 2006; St George-Hyslop, et al., 1987).  
 
The second defining characteristic of AD is the presence of neurofibrillary tangles (NFTs) comprised of 
intracellular accumulations of the microtubule-associated protein tau in affected neurons (Ballatore, et al., 
2007). The extent of tau pathology in human AD has been shown to correlate well to disease severity (Braak 
and Braak, 1991). Mutations in the gene encoding tau (MAPT) have been found to be causal for fronto-
temporal dementia, although MAPT mutations have not been described in AD (Hutton, et al., 1998; Spillantini, 
et al., 1998). Overexpression of tau protein in mouse models has been shown to disrupt intracellular 
trafficking (Zhang, et al., 2006), to induce axonal degeneration (Spittaels, et al., 1999), and the humanized tau 
overexpression leads to neurofibrillary tangles formation in vivo (for review, see (Götz, et al., 2007)). A 
number of promising drugs have reached late-stage (Phase III) clinical testing, however then failed to prevent 
cognitive decline (Doody, et al., 2013; Doody, et al., 2014; Salloway, et al., 2014). The reasons are likely two-
fold: first, the lack of human data for the successful stratification (separating patient population) according to 
disease phenotypes and/or genetic risk profiles (Blennow, 2010; Wolozin, 2012), and second, the species 
gap. Risk factors present in humans may not be adequately modeled in rodents. For example, while variants 
in the APOE gene are the strongest genetic risk factors for sporadic AD identified to date (Bertram, et al., 
2008; Corder, et al., 1993; Farrer, et al., 1997), the rodent genome has only one version of this gene.  
 
A number of elegant mouse models have allowed the study of AD phenotypes in vivo in the brain, and have 
resulted in the basis of our current mechanistic understanding of the disease. However, a common drawback 
to these models is that they typically only capture specific aspects of AD phenotypes such as A or NFTs, but 
rarely the entire disease spectrum (Webster, et al., 2014). Moreover, most mouse models focus only on the 
causative mutations in familial AD (fAD), such as those in the genes encoding presenilin 1 and 2 (PSEN1, 
PSEN2) and the amyloid-precursor protein (APP). These cases represent an extremely small percentage of 
the overall human AD burden; though models of fAD are invaluable, the majority of AD cases are sporadic 
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(sAD). The genetic underpinnings of sAD may result from a combinatorial or additive effect of single 
nucleotide polymorphisms (SNPs) identified in genome-wide association studies (GWAS) (Lambert, et al., 
2013), while disease penetrance may depend on a host of non-genetic risk factors, such as age, head 
trauma, diabetes, lifetime stress, and environmental toxins, amongst others. Studying the distinct impact of 
AD-associated SNPs in mouse models is challenging, as these variants are often found in non-coding regions 
of the human genome. Using even the latest and most rapid genome editing techniques to insert multiple 
SNPs in homologous mouse genome regions would be onerous, expensive, and could be considered a high-
risk undertaking. It is often not known whether a single SNP is disease causing, or whether it’s a combination 
of several SNPs particularly as a number of different SNPs are commonly ascribed to a single locus.  
 
1. Human induced pluripotent stem (iPS) cells  
 
We will summarize the history, generation, and differentiation of human iPS cells only briefly, as many 
excellent reviews have covered these topics (Bouwman and de Laat, 2015; Parent and Anderson, 2015; 
Telias and Ben-Yosef, 2014). One fundamental question in the regeneration field is to find cells that maintain 
the capability to differentiate into the three germ layers: endoderm, mesoderm, and ectoderm. Embryonic 
stem (ES) cells have this “pluripotency” capability (Evans and Kaufman, 1981; Martin, 1981; Thomson, et al., 
1998). However, ethical issues tempered the initial excitement for human ES cells and therefore alternative 
strategies were needed (Hotta, 2008; Kamm, 2005). An important step was the discovery that the content of 
an oocyte’s cytoplasm contained factors crucial for reprogramming somatic cells to an embryonic-like stage 
(Cowan, et al., 2005; Tada, et al., 2001; Wilmut, et al., 1997). Takahashi et al. screened 24 of these factors 
and demonstrated that Oct3/4, Sox2, c-Myc, and Klf4 induced pluripotent stem cells from adult mouse 
fibroblasts (Takahashi and Yamanaka, 2006). A year later, the same group showed that they could reprogram 
human fibroblasts with these four “Yamanaka factors” into human pluripotent stem cells (Takahashi, et al., 
2007). Other groups have generated similarly pluripotent cells from other peripheral cells, such as blood cells 
(Okita, et al., 2013) or urine-derived epithelial cells (Zhou, et al., 2012).To distinguish these pluripotent stem 
cells from ES cells, the cells were named “induced pluripotent stem” (iPS) cells. Currently, much debate exists 
over the best method for reprogramming somatic cells into iPS cells, as well as how to assess the “stemness” 
of an iPS cell as compared to an ES cell line (Bock, et al., 2011; Hanna, et al., 2010; Lister, et al., 2011). It is 
important to keep in mind that exogenous factors, genetic background, and epigenetic of tissue origin of cells 
influences naïve pluripotency (Hanna, et al., 2010). Therefore certain differences on the epigenetic landscape 
are expected to exist between ES and iPS cells (Bock, et al., 2011; Lister, et al., 2011). Nevertheless, the 
advent of iPS cells allows to generate any cell type of interest from a patient’s own somatic cells and to 
develop patient-specific drug treatments. Moreover, these techniques offer a nearly unlimited supply of human 
cells that can be deposited in repositories and shared between laboratories.  
 
2. Advantages to modeling neurological disease with iPS cells 
 
The study of human brain disease is hampered by obtaining live material. The ability to generate neural 
cultures from post-mortem human brains depends greatly on the quality of the post-mortem brain tissue 
(Verwer, et al., 2002). Prolonged agonal states such as hypoxia, coma, or ischemic brain damage could add 
confounding variables to these studies (Monoranu, et al., 2009). This is not to mention the sheer difficulty of 
gaining access to reliable sources of human brain tissue. The generation of human iPS cells is one way to 
surmount these limitations. Protocols have been developed to differentiate iPS cells in vitro into distinct cell 
types allowing researchers to examine disease onset and progression directly in a human culture model (Liu, 
et al., 2012; Sandoe and Eggan, 2013). A number of studies have shown successful reprogramming of iPS 
cells from fibroblasts derived from individuals with various neurological diseases such as amyotrophic lateral 
sclerosis (Dimos, et al., 2008), familial dysautonomia (Lee, et al., 2009), Parkinson’s disease (Park, et al., 
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2008; Soldner, et al., 2009), Rett syndrome (Marchetto, et al., 2010), schizophrenia (Brennand, et al., 2011), 
spinal muscular atrophy (Ebert, et al., 2009; Yoshida, et al., 2015), ADA-SCID, Gaucher disease type III, 
Duchenne muscular dystrophy, Becker muscular dystrophy, Down syndrome, Juvenile diabetes mellitus, 
Huntington disease (Consortium, 2012; Zhang, et al., 2010), and Lesch-Nyhan syndrome (Mattis, et al., 2015; 
Park, et al., 2008) and AD (Choi, et al., 2014; Hossini, et al., 2015; Iovino, et al., 2015; Israel, et al., 2012; 
Koch, et al., 2012; Kondo, et al., 2013; Muratore, et al., 2014; Wren, et al., 2015; Yagi, et al., 2011; Table 1). 
 
3. Drawbacks of iPS cells in neurological disease modeling 
 
The explosion in human iPS cell use has underscored the need to establish standardized protocols, as cell 
handling and other factors can influence phenotypes (Boulting, et al., 2011). For example, variable X-
inactivation in cells from female donors can have an impact upon both differentiation and phenotype (Boulting, 
et al., 2011). Also, there is still debate regarding to what extent DNA methylation profiles, and other epigenetic 
attributes, might be maintained in iPS cells after reprogramming (Kim, et al., 2010; Koche, et al., 2011; Nazor, 
et al., 2012; Ohi, et al., 2011). To determine the magnitude and nature of variability amongst human iPS cells, 
(Bock, et al., 2011) performed a human genome-wide reference mapping of the DNA methylation across 20 
ES and 12 iPS cell lines. They established two scorecards for evaluating the quality and utility of human 
pluripotent cell lines; this kind of tool is crucial to the standardization of iPS protocols and is needed to obtain 
comparable and reproducible results.   
 
Genetic diversity within and between populations, as well as disease onset and progression, can impact the 
experimental read-out from iPS cells (Rouhani, et al., 2014; Soldner and Jaenisch, 2012). For example, 
common DNA variants may alter expression levels and pattern of many human genes (Majewski and 
Pastinen, 2011). Some groups have sought to overcome this diversity by focusing either on few phenotypes in 
a large collection of lines (Bock, et al., 2011; Rouhani, et al., 2014; Yoshimizu, et al., 2015), or by 
investigating robust phenotypes in a smaller cohort (Chung, et al., 2013; Israel, et al., 2012). Each iPS cell 
study is challenged by the question of to what extent the observed phenotypes are related to the disease 
being modeled. For example, is the phenotype influenced by protective or exacerbating factors in the 
individual’s genotype? Recent advances in genome editing techniques, particularly the use of Cas9 nuclease-
based strategies, have made the generation of isogenic iPS cell practicable (Zhang, et al., 2014) and this 
technology can address the variability inherent in the human genome to some extent. 
 
4. Creating isogenic iPS cell lines as a strategy to overcome variability in human genomes  
 
The advent of homology-directed repair techniques for genome editing proved a major advance in our ability 
to manipulate the human genome. Currently, three systems have been established to perform DNA repair- 
directed genome editing: Zinc-Finger-Nucleases (ZFN), transcription activator-like effector nucleases 
(TALENs), and the clustered regularly interspaced short palindromic repeats (CRISPR) system that uses the 
Cas9 nuclease. All these nucleases induce guided DNA breaks. The repair of these breaks then either leads 
to insertion or deletion (indel) mutations, or the break can be repaired by homologous recombination with a 
donor vector carrying the desired mutation (Byrne, et al., 2014). For a detailed review of the function of each 
of the nucleases, please refer to the reviews from (Hsu, et al., 2014; Sander and Joung, 2014) as well as to 
descriptions of experimental strategies and protocols for human pluripotent cells in particular (Byrne, et al., 
2014; Chiba and Hockemeyer, 2015; Zhu, et al., 2014).  
 
The first generation of enzyme-directed genome editing used ZFNs. A number of important papers used the 
first generation ZFNs to generate isogenic iPS cells (Carroll, 2011; Urnov, et al., 2010)) by knocking down 
genes such as PITX3 (Hockemeyer, et al., 2009) or PIG-A (Zou, et al., 2009), or correcting disease-related 
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mutations in genes such as α1-anti-trypsin (Yusa, et al., 2011), α-synuclein (SCNA;(Ryan, et al., 2013; 
Soldner, et al., 2011), and tau (MAPT(Fong, et al., 2013). However, the success of this technique is limited 
due to the challenging design of a robust engineered zinc finger nuclease (Hsu, et al., 2014; Ma, et al., 2015; 
Sander and Joung, 2014). The development of the second generation TALEN technique overcame some of 
the limitations of the ZFNs by being less context-dependent and easier to design (Joung and Sander, 2013; 
Miller, et al., 2011; Sander and Joung, 2014), while the efficiency is similar between the two paradigms 
(Hockemeyer, et al., 2011). Human iPS models established with TALEN technology include manipulations in 
the APOB, SORT1, AKT2, PLIN1 (Ding, et al., 2013), PSEN1 (Woodruff, et al., 2013), and DISC1 (Wen, et 
al., 2014). The third generation of genome editing tools is comprised of the CRISPR/Cas9 systems, which are 
based on the use of the RNA-guided Cas9 nuclease (Jinek, et al., 2012; Mali, et al., 2013; Ran, et al., 2013). 
One major advantage of the CRISPR system is that the Cas9 component is fixed, and the targeting sequence 
is supplied via a single-guide RNA (sgRNA); thus, targeting sequences can be easily exchanged or 
multiplexed by testing multiple sgRNAs (Ding, et al., 2013). Several groups generated iPS cells that stably or 
inducible express the Cas9 protein. This system allows for rapid cell-based screens to test the consequences 
of multiple gene knockdowns using sgRNA libraries (Shalem, et al., 2014; Wang, et al., 2014; Zhu, et al., 
2014). Algorithms have been developed that predict off target effects of CRISPR-mediated genome editing, 
which, combined with falling costs for deep sequencing, allow researchers to minimize off-target effects (Hsu, 
et al., 2013; Tsai, et al., 2015).  
 
The advantage of isogenic lines is that only the disease-associated difference is studied, as the genetic 
background of the lines should be identical. While this is ideal for the study of disease causative mutations, 
other genetic variants, such as a haplotype of SNPs, are more difficult to model because they may only be 
relevant to disease risk in combination. Therefore, it seems advisable to both correct the mutation of interest 
in a patient-derived cell line, while in parallel introducing it in a control line. Techniques using mutated Cas9 
linked to transcriptional activators or repressors also allow us to examine the consequences of enhanced or 
suppressed expression of specific genes without alterations to the genome itself (Qi, et al., 2013). Therefore, 
genome editing will be an important strategy to minimize the effect of background variations in human iPS 
cell-derived lines.  
 
5. iPS cells as a model for understanding AD onset and disease progression 
 
In the following chapter, we will focus on studies that use iPS cells to model AD-like phenotypes (summarized 
in Table 1). The two hallmark characteristics of AD in the human brain are first, accumulation of -amyloid 
(A) peptides into extracellular aggregates (A plaques), and second, the intracellular accumulation of 
phosphorylated species of the microtubule-associated protein tau into neurofibrillary tangles (NFTs). Both 
parameters can be measured in vitro: alterations in the presence of Aβ peptides can be measured from 
culture medium or cell lysates, and the ratios between different species of Aβ peptides, such as the amount of 
Aβ40 versus Aβ42, are often reported. To examine tauopathy in AD cellular models, the abundance of different 
species of phosphorylated tau (pTau) is normalized against total tau levels. Other AD-like phenotypes that 
can be measured in cultured cells will also be discussed, including endosome cycling and DNA damage. 
 
5a. Phenotypic characterization of iPS cell AD models 
 
Several groups have succeeded in creating functional neurons from fAD and sAD iPS cells: In 2011, Yagi et 
al. used fibroblasts of fAD patients with mutations in either presenilin isoform PSEN1 (A246E) or PSEN2 
(N141I; Yagi, et al., 2011). Using retrovirus carrying a five-factor reprogramming mix of OCT4, SOX2, KLF4, 
LIN28 and NANOG, they created iPS cells that were then differentiated mainly into neuronal cells. After two-
week culturing, they observed an elevated ratio of Aβ42 to Aβ40 for the fAD lines compared to controls. The 
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authors did not find any level of tauopathy, and speculated that the two-week maturation time may have been 
too short. Treatment of the cultures with the -secretase inhibitors Compound E and Compound W reduced 
both Aβ40 and Aβ42 levels, while only the highest dose of Compound W appeared to impact the Aβ42/40 ratio. 
This study was the first to establish a model of fAD phenotypes in iPS cell-derived neural cultures. However 
the drawbacks of this work might be the relatively short time of neuron maturation as well as the potential high 
variability between clones of the same genotype.  
 
In 2012, Israel et al. provided a thorough evaluation of AD-like phenotypes in multiple iPS cell-derived 
neurons from both fAD and sAD individuals (Israel, et al., 2012). They used retrovirus carrying the four 
Yamanaka factors OCT4, SOX2, KLF4, and c-MYC to create iPS cells lines from healthy, non-demented 
individuals, two sporadic AD patients, and two familial patients, who carried APP duplications. Neural 
progenitor cells were purified using fluorescence activated cell sorting and differentiated into heterogeneous 
neuronal cultures. They observed increased secreted Aβ40 in neurons created from one sAD and the two fAD 
lines. Importantly, the Aβ levels did not differ in fibroblasts from the same individuals, supporting the idea that 
only distinct iPS-derived cells can model disease-specific phenotypes. No changes were observed in the 
Aβ42/40 or Aβ38/40 ratios between cell lines, although the authors noted that detection of the less abundant Aβ42 
and Aβ38 species were often below the detection range of the assay due to the small number of neurons. In a 
similar pattern, one sAD and both fAD lines showed increased phospho-tau and activation of the tau kinase 
GSK3β. Treatment of the neuronal cultures with - and β-secretase inhibitors reduced Aβ40 in one sAD and 
one fAD line, while only β-secretase inhibitors lowered the levels of active GSK-3β, and phospho-tau. Another 
AD phenotype that can be characterized in iPS cell-derived cultures is the presence of abnormal endosomes.  
Large, RAB5-positive early endosomes have been observed in AD mouse models and in the brains of sAD 
and fAD patients (Cataldo, et al., 2001; Cataldo, et al., 2000). These endosomes may contain aberrantly 
phosphorylated Aβ (Lee, et al., 2003). Impaired endocytic and mitochondrial trafficking has also been 
observed in iPS cell models of frontotemporal dementia (FTD) using cells from patients carrying mutations in 
the MAPT gene (Iovino, et al., 2015; Wren, et al., 2015). Israel et al. examined early endosome morphology in 
iPS-derived neurons seeded onto a layer of commercially-available human astrocytes, and found that the 
number of medium to large RAB5+ endosomes was increased in neurons derived from one sAD and one fAD 
compared to the two controls, when they examined early endosome morphology in iPS-derived neurons 
seeded onto a layer of commercially-available human astrocytes. Finally, they measured synapse formation 
and function. No differences were apparent in synapse number (synapsin immunoreactivity) or function 
(voltage clamp recordings) between the AD and control lines.  
 
In 2013, Kondo et al. used episomal vectors to generate iPS cells from dermal fibroblasts from both sAD 
patients and fAD patients carrying the APP-V717L or the APP-E693Δ fAD mutations (Kondo, et al., 2013). 
The E693Δ mutation leads to early-onset AD, but without amyloid deposition. Differentiated E693Δ neurons 
showed decreased Aβ40 and Aβ42 compared to controls, while neurons from the V717L line have increased 
extracellular Aβ and an increased Aβ42/40 ratio. No significant Aβ secretion was detectable in the medium of 
the sAD lines. The authors then established astrocyte-rich cultures using protocols modified from Su-Chun 
Zhang’s work (Krencik and Zhang, 2011). Astrocytes from the E693Δ line and one of the sAD lines 
accumulated Aβ oligomers intracellular. They performed gene expression profiling of the astrocyte/neuronal 
co-cultures from E693Δ and control cells and observed that oxidative stress-related categories were 
upregulated in the AD lines, suggesting ER and Golgi perturbation. The levels of these genes were reduced 
following treatment with DHA, known to alleviate oxidative stress, as well as the production of ROS, in E693Δ 
cells, without altering the levels of Aβ.  
 
Fong et al (2013) used zinc-finger nucleases (ZFNs) to correct a A152T mutation in the MAPT gene (tau), as 
well as to create an isogenic line homozygous for the mutation, in iPS cells (Fong, et al., 2013). Following 
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neuronal differentiation, the heterozygous mutant tau neurons showed short, misshapen neurites with 
punctate tau and significant phospho-tau immunoreactivity. These phenotypes were absent in the corrected 
lines, and were significantly exacerbated in the homozygous mutant lines, which showed high degrees of 
phospho-tau (AT8) and blebbing of the neurites. While they found a low percentage of dopaminergic cells 
(DA) in the mutant lines, the corrected isogenic lines had 4 to 8-fold increased number of DA neurons.  
 
In addition to lines derived from AD patients, several groups have overexpressed fAD mutant versions of 
PSEN1 or APP in healthy iPS or ES cell lines (Choi, et al., 2014; Koch, et al., 2012). For example, neurons 
created from a human ES cell line were transduced, as neuroepithelial-like stem cells, with lentivirus carrying 
cDNAs for PSEN1wt, PSEN1D385N, or PSEN1L166P under control of the EF1alpha promoter (Koch, et al., 2012). 
By four weeks of neuronal differentiation, most of the β-III tubulin–positive cells were highly immunoreactive 
for APP. Interestingly, the inclusion of Exon 15 of APP, a splice variant associated with neurons, was present 
in neurons after 4 weeks compared to undifferentiated cells. Extracellular Aβ level was reduced in these 
neuronal cultures following treatment with the -secretase inhibitor DAPT. In addition, NSAIDS, such as 
ibuprofen, slightly lowered Aβ levels only in the PS1wt, but not the PS1D385N, overexpressing neurons. One 
early screening effort used commercially available iPS cell-derived neurons (iCell Neurons) to screen a library 
of several hundred compounds for their ability to ameliorate toxicity from exogenously applied Aβ (Xu, et al., 
2013). 
 
To date, most studies model AD in patient-derived iPS cells utilize cell lines with defined fAD mutations in 
PSEN1 and APP. While some studies include cells from sAD patients, the lack of a defined mutation means 
that isogenic lines cannot be made, and often information is lacking as to the severity or course of disease 
progression. Two studies in which sAD lines were included observed disease phenotypes similar to fAD cells 
in only one of two sAD samples (Israel, et al., 2012; Kondo, et al., 2013). Few studies include sAD lines, and 
this is a concern, as sporadic late-onset AD represents the vast majority of AD cases. And while 60-80% of 
sAD may in fact have genetic underpinnings (Gatz, et al., 2006), one’s APOE genotype remains the only 
robust factor affecting sAD risk. These issues add to the call for development of AD biomarkers that can 
predict disease risk and age of onset. Much work has begun in this direction, and large-scale human genome-
wide association studies (GWAS) combined with mouse and human epigenetic and transcriptome profiling, 
have derived lists of genes in which variants are consistently associated with an increased risk of AD 
(Bertram, et al., 2007). These genes tend to be implicated in vesicle trafficking/endocytosis, immune function, 
and cholesterol metabolism (for review see Olgiati, et al., 2011)). One recent study (Young, et al., 2015) 
focused upon iPS cells derived from individuals with sAD-associated variants in the SORL1 gene, which 
encodes a protein involved in endocytic trafficking, and whose loss of expression has been observed in sAD 
brains. The authors found that the induction of SORL1 expression by brain-derived neurotrophic factor 
(BDNF) treatment, as well as the effect of SORL1 expression upon Aβ secretion, was affected by SORL1 
genotype in differentiated human neurons. While these studies were hampered by significant variability, which 
was combated by the inclusion of a relatively large number of cell lines, it was the first to describe a 
phenotype in human iPS cell-derived neurons resulting from sAD-associated genetic variants. With the 
increased feasibility of genome editing in iPS cells, particularly to create point mutations, we anticipate that 
the near future will see many more reports elucidating the roles of sAD risk variants in iPS cell-derived neural 
cell models. 
 
5b. AD phenotypes in Down syndrome iPS cells 
 
Down Syndrome (DS) patients show a high incidence of early-onset AD-like dementia (40-60%). The 
underlying reasons for this are not clear, but are presumably related to the triplication of the APP gene, as 
well as the tau kinase Dyrk1a gene (Woods, et al., 2001) on chromosome 21 (Beyreuther, et al., 1993; Burger 
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and Vogel, 1973; Lemere, et al., 1996; Rumble, et al., 1989). Therefore, neural cell models from DS 
individuals may improve both our understanding of AD-like pathology, as well as providing hope for therapies 
for DS (2013). To date, no genome editing protocols have been reported that allow for the correction or 
induction of trisomy in iPS cell models. However, the rare occurrence of monozygotic twins discordant for 
trisomy 21 (Hibaoui, et al., 2014), as well as creation of iPS cell lines from individuals with mosaic DS 
(Murray, et al., 2015; Weick, et al., 2013), and the spontaneous reversion to disomy 21 in a DS iPS cell line 
(Maclean, et al., 2012), provide us with isogenic lines with which to study this disorder. An early paper (2008) 
demonstrated AD-like deficits in endocytic function in fibroblasts from DS individuals (Cataldo, et al., 2008). In 
2012, the Livesey group created iPS cells from one DS patient and one control and examined them for AD-
like pathology (Shi, et al., 2012). Interestingly, the DS line secreted far higher levels of both Aβ40 and Aβ42 as 
fibroblasts, than did control cells. Following two months in neuronal culture, aggregates of Aβ42 were detected 
in the DS cultures using live staining with the thioflavin T analog, BTA1 and immunocytochemistry against 
Aβ42. A twenty-one day treatment with DAPT nearly abolished both species of Aβ production in the DS 
neurons. Tau pathology was also evident in neurons differentiated from DS iPS cells, detectable as an 
abnormal distribution of phospho-tau within the neurons as well as secreted tau in the medium of DS cultures 
only. Synapse formation did not appear to differ between neurons from DS and control individuals.  
 
Chang et al (2015) created neurons from both hES cell and iPS cell lines (Chang, et al., 2015). Similar to Shi 
et al, the authors found increased immunoreactivity for Aβ and phosphorylated tau. Treatment with n-
butylidenephthalide (Bdph), an activator of Wnt signaling, delivered via coated nanoparticles, ameliorated AD-
like phenotypes in these cultures. Recently, accelerated aging phenotypes were reported in neurons derived 
from DS iPS cells compared to isogenic controls (Murray, et al., 2015). Unlike previous models, these cells 
exhibited differences in proliferation and differentiation. Consistent with earlier reports, the DS iPS cell-derived 
neurons had increased Aβ immunoreactivity in fixed cultures, but did not appear to differ electrophysiologically 
from controls. The DS neurons also exhibit mitochondrial dysfunction and increased DNA damage compared 
to the controls. This last phenotype is particularly interesting, and the failure of neurons to maintain their 
genomic integrity appears to be a hallmark both of normal aging and of neurodegenerative disease (Dobbin, 
et al., 2013; Goto, 1997; Hasty, et al., 2003; Kim, et al., 2008; Lovell and Markesbery, 2007; Lu, et al., 2004; 
Sahin and DePinho, 2010; Wang, et al., 2013). In conclusion, iPS cell-derived neurons from DS individuals 
may be useful for modeling phenotypes that are similar between AD and aging in DS, as these cells appear to 
exhibit both amyloid and tau pathology as well as phenotypes such as endosome dysfunction and DNA 
damage.   
 
6. Disadvantages in modeling AD with iPS cells 
 
6a. Aging in iPS cells 
Work by several groups has suggested that reprogramming of the iPS cells “re-set” the epigenome, and that 
other phenotypes associated with cellular aging, such as mitochondrial function and telomere length, are 
returned to a “juvenile-like” state (Mahmoudi and Brunet, 2012; Miller and Studer, 2014). This raises the 
question: can we model phenotypes associated with aging in human neural cells (Isobe, et al., 2014)? 
Transplantation studies of human neuronal progenitor cells (NPCs) into the rodent brain have suggested that 
the human neural cells mature on a human, rather than a rodent, timeline (Espuny-Camacho, et al., 2013). 
However, simply allowing iPS cells-derived neural cells to age in vitro is impracticable and expensive. 
Therefore, several groups have begun to explore the possibility of accelerated aging in these model systems. 
One approach is to derive iPS cells from individual with Hutchinson-Gilford Progeria syndrome (HGPS), which 
maintain a truncated product of the mutated LMNA gene, progerin, which triggers fast aging (Blondel, et al., 
2014; Liu, et al., 2011). Liu et al found that the deleterious progerin protein was absent in HGPS patient-
derived cells in the iPS cell stage (Liu, et al., 2011). However, upon differentiation to smooth muscle cells, the 
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disease phenotype of progerin accumulation, as well as its ageing-associated cellular defects, were 
recapitulated. In place of using patient cells, progerin can also simply be overexpressed in iPS cells to induce 
age-related phenotypes such as DNA damage and mitochondrial dysfunction (Miller, et al., 2013). Increases 
in DNA damage have also been observed in iPS cells derived from individuals with Werner Syndrome, an 
accelerated aging disorder arising from mutations in the WRN gene, which encodes a DNA helicase 
(Shimamoto, et al., 2015).  
 
Instead of progerin overexpression, other “stimulating” factors might be used, which activate aging pathways. 
An interesting example has been shown for cardiomyocytes from differentiated iPS cells of patients with 
arrhythmogenic right ventricular dysplasia. These cells were exposed to a three-factor cocktail, which 
activates PPAR and leads to increased fatty acid oxidation instead of glycolysis (Wen, et al., 2015). In this 
way, the authors recapitulate the adult cardiomyocyte-like metabolism in these cells, which could be pushed 
to the desired disease pathologies by further treatment with PPAR activators. Although these techniques 
appear to induce aging phenotypes in iPS cell derivatives, we first have to understand the underlying 
association of aging with AD to incorporate systematic approaches to age neurons.   
 
6b. Neuronal Maturation 
In all iPS cell approaches, it is necessary to confirm the maturity and the functionality of the derived neurons. 
While some studies in neurodegenerative disorders use nestin and Pax6-positive NPCs as a kind of proxy to 
neurons (Hossini, et al., 2015), others have gone to lengths to demonstrate the degree to which iPS cell-
derived neurons model in vivo human neurons (Israel, et al., 2012). The most common methods to confirm 
neuronal differentiation and matureness are a combination of immunocytochemistry and electrophysiology 
(Israel, et al., 2012; Nieweg, et al., 2015): Mature neurons should show the ability to fire action potentials 
when depolarized under current clamp, as well as demonstrating spontaneous excitatory and inhibitory 
postsynaptic currents under single-cell patch-clamp. Immunocytochemistry for synaptic vesicle proteins, such 
as VGLUT1, VAMP2, synaptobrevin, and synapsin, are indicative for mature functional synapses (Marchetto, 
et al., 2010; Nieweg, et al., 2015). One early screening effort emphasized the need to create mature neuronal 
cultures for reliable drug assays (Yahata, et al., 2011). Thus, one major challenge to researchers is to provide 
neuronal cultures that are both mature enough to be representative of adult brain neurons, while being 
abundant enough for multiple types of assays. Occasionally the presence of disease mutations may hamper 
efforts to create human neural cell models of disease. For example, neurons created from patient-derived iPS 
cells carrying FTD mutations in MAPT have been shown to mature more quickly than control lines, while at 
the same time displaying disease phenotypes such as hyperphosphorylated Tau (Iovino, et al., 2015). In 
contrast, another group using iPS cell-derived neurons carrying the same MAPT mutation (N279K) reported 
that these cells had deficits in neuronal maturation compared to control lines (Wren, et al., 2015). The issue of 
altered proliferation and/or differentiation of neural progenitor cells and neurons seems particularly 
troublesome in work with Down syndrome lines (Hibaoui, et al., 2014; Murray, et al., 2015).  
 
6c. Culture Heterogeneity and Disease Phenotypes 
Another important aspect is that in several studies it is not obvious to what extent the reported neuronal 
cultures contain other cell types, nor whether heterogeneous cultures may encourage neuronal differentiation 
(Sandoe and Eggan, 2013; Shi, et al., 2012; Shi, et al., 2012). While pure cultures of neurons can form 
synapses and display connectivity, they may not mature fully in the absence of astrocytes or glial-conditioned 
medium (Pfrieger, 2009; Pfrieger and Barres, 1997; Ullian, et al., 2004). Along these lines, some groups have 
found that the addition of astrocytes to iPS cell-derived neuronal cultures enhances the ability to obtain 
mature neurons (Odawara, et al., 2014; Zhang, et al., 2013); this is an area of active debate and constant 
methodological improvement. Overall, it is necessary to fully characterize the cell type matureness as well as 
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the heterogeneity of neural cultures derived from iPS cells. In this regard, the advent of three-dimensional 
neural cultures derived from human iPS cells may be particularly beneficial as discussed later. 
 
Finally, a major challenge is to generate a distinct cell type to study its involvement in a disease phenotype. It 
is hypothesized that only a certain subset of cells fails in many neurological diseases, for example, a 
subpopulation of dopaminergic cells in Parkinson’s disease (Sandoe and Eggan, 2013). Moreover, the 
phenotypes displayed by cells bearing physiological mutations, such as familial AD mutations, may often be 
less robust than those obtained via the experimental overexpression of mutant proteins. One study compared 
the effect of compound treatment on neural cells from fAD patients to either heterologous cell lines 
overexpressing fAD APP, or human control ES-derived neural cells overexpressing mutant APP. They 
observed that concentrations of indomethacin that reduced Aβ42/40 robustly in the heterologous cells, and 
more modestly in the APP-overexpressing human cells, had no effect on the human neural cells carrying 
endogenous fAD mutations (Mertens, et al., 2013). Most researchers who use patient-derived iPS cells 
carrying familial mutations will be familiar with this issue of comparatively mild disease phenotypes, at least 
compared to models of gene overexpression or knockdown. Fortunately, the use of isogenic lines with 
corrected disease alleles may, by reducing variability between lines, allow for the reliable measurement of 
even modest phenotypes. The increased use of three-dimensional tissue culture systems (see Section 8), 
may also facilitate disease phenotypes by concentrating protein aggregates and other cellular products in a 
tissue-like environment that can still be imaged or assayed with ease.  
 
In addition to the issue of variability between iPS cell-derived lines in assays of disease phenotypes, we are 
faced with the growing awareness that other cell types must be created to model AD in these systems. For 
example, in the last decade, it has become obvious that glia cells have an important impact in disease onset 
and progression. Thus, our basic science interests demand that we increase the complexity of our cellular 
models to adequately represent the disease, while at the same time we are tasked with the production of 
simplified systems that are amenable to applications such as drug screening. 
 
7. Differentiation of iPS cells to study cell type-specific impact towards neurological diseases 
 
Generation of iPS cells typically serves as a starting point to differentiate them into various brain-specific cell 
types such as neurons or glial cells. Each cell lineage develops, when a combination of exogenous 
morphogens are applied at distinct time points during development of the iPS cells (Liu and Zhang, 2011). An 
alternative strategy is the overexpression of cell type-specific transcription factors (Zhang, et al., 2013). In the 
following, we focus on examples of the successful generation of neuronal and glial cell types from human iPS 
cells.  
 
7a. Differentiation to distinct neuronal cell types 
The initial iPS cell study by Takahashi et al. demonstrated the successful generation of neuronal cells from 
iPS cells (Takahashi, et al., 2007). It is now common to perform neuronal differentiation (Denham and Dottori, 
2011), and even to differentiate into specific neuronal subtypes, such as forebrain glutamatergic neurons 
(Zeng, et al., 2010), cortical neurons (Nieweg, et al., 2015; Shi, et al., 2012), GABAergic interneurons (Liu, et 
al., 2013; Nieweg, et al., 2015), motor neurons (Ebert, et al., 2009), and hypothalamic-like neurons (Wang, et 
al., 2015). Indeed, there are too many neuronal differentiation techniques in the literature to adequately review 
here (some recent reviews include (Broccoli, et al., 2015; Broccoli, et al., 2014; Chinchalongporn, et al., 2015; 
Lai, et al., 2015)). The generation of inhibitory neurons is of particular interest for AD research, since both 
inhibitory and excitatory neurons are affected (Hazra, et al., 2013; Krantic, et al., 2012), and inhibitory 
interneurons, such as parvalbuminergic cells, play crucial roles in orchestrating large networks crucial to 
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memory formation (Bartos, et al., 2007; Mann and Paulsen, 2007). The development of protocols for the 
differentiation of multiple neural subtypes is a lively area of research.  
 
7b. Differentiation to glia 
In the brain, glial cells can be divided in three major cell classes: astrocytes, microglia, and oligodendrocytes. 
Each of them has been proposed to have an important impact in AD’s onset and progression; even so it is still 
debatable, whether they are causative for the disease or just represent a secondary by-standing effect. 
Overall human AD and mouse gene expression studies show that with AD progression, immune response 
and inflammatory genes are up- and genes involved in neuronal functions are down-regulated (Blalock, et al., 
2011; Blalock, et al., 2004; Gjoneska, et al., 2015). Interestingly, GWAS describe several AD-risk increasing 
genetic variants, which are linked to genes with identified roles in glial cells, such as APOE, PICALM, TREM2, 
CR1, CD33 and CLU (Ando, et al., 2013; Antunez, et al., 2011; Bertram, et al., 2008; Bradshaw, et al., 2013; 
Calero, et al., 2000; Corneveaux, et al., 2010; Crehan, et al., 2013; Deng, et al., 2012; Guerreiro, et al., 2013; 
Harold, et al., 2009; Hollingworth, et al., 2011; Jonsson, et al., 2013; Lambert, et al., 2009; Lambert, et al., 
2010; Wunderlich, et al., 2013; Zhang, et al., 2010). Apolipoprotein APOE was originally identified in the liver 
that mediates the transport and delivery of cholesterol and other lipids through cell surface ApoE receptors 
(Mahley, 1988; Mahley and Rall, 2000). The human APOE gene exists as three alleles. While these three 
variants have a frequency in the population of 8.4% (ε2), 77.9% (ε3), and 13.7% (ε4), the frequency of the 
APOE ε4 variant (APOE4) is increased to at least 40% in sporadic AD patients (Farrer, et al., 1997) making it 
as one of the greatest risk factors for sAD (Kanekiyo, et al., 2014; Lambert, et al., 2013). Individuals with one 
APOE4 allele are three to four times as likely to develop AD than those without APOE4 alleles, an odds ratio 
that is by far the highest out of any AD risk gene (Bertram and Tanzi, 2008; Corder, et al., 1993). In both 
humans and in animal models, the APOE4 allele is associated with increased levels of amyloid beta (A), as 
well as amyloid plaque deposition (Castellano, et al., 2011; Fryer, et al., 2005; Kim, et al., 2009; Youmans, et 
al., 2012). The least common variant, APOE2, differs from the APOE4 variant at just two amino acid positions 
but appears to be protective against the development of AD (Bu, 2009; Corder, et al., 1993; Liu, et al., 2013). 
While the contribution of the APOE4 allele to AD risk is well known, the reasons why this variant may trigger 
AD are not at all understood. The study of these APOE variants has been particularly difficult in rodent 
models, which endogenously express only one version of the Apoe gene. Thus, the emergence of iPS cell 
lines with different APOE isotypes will greatly advance our understanding of this AD risk factor by either 
collecting individuals of particular genotypes, or by using genome editing to “switch” between the protective 
and the disease-causing APOE form within one line. 
 
Taken together, two important themes emerge from these observations: 1) neurodegeneration in AD most 
likely involves an interaction of neuronal and glial pathologies; and 2) understanding the functions of genes 
implicated in AD, from GWAS or expression studies, will require a thorough characterization of their functions 
in a cell type-specific manner. Since human and mouse glia are surprisingly divergent (Oberheim, et al., 2006; 
Oberheim, et al., 2009), which places emphasis on the need for models of human glia for the study of 
neurodegenerative disease.  
 
Astrocytes 
Astrocytes are a diverse cell class, which can differ both functionally and morphologically between brain 
regions (Bribian, et al., 2015; Ma, et al., 1999; Tabata, 2015) as well as displaying significant species 
divergence (Oberheim, et al., 2006; Oberheim, et al., 2009). Astrocytes are intimately involved in 
synaptogenesis and synapse maintenance (Haydon and Nedergaard, 2015; Pascual, et al., 2005; Perea, et 
al., 2009), maintain brain homeostasis, store and distribute energy substrates, and play a major role in the 
clearance of metabolites and toxins from the brain parenchyma (Jessen, et al., 2015; Xie, et al., 2013). 
Inflammatory astrogliosis precede or accompany neurodegeneration in many animal models and human 
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postmortem AD brains, as evidenced by increased immunoreactivity for glial fibrillary acidic protein (GFAP) as 
well as by the loss of important astrocytic proteins such as glutamine synthase and GLT-1 (Dabir, et al., 2006; 
Fischer, et al., 2005; Li, et al., 1997; Masliah, et al., 2000; Robinson, 2001; Tilleux and Hermans, 2007). 
Moreover, astrocytes in the brain are the primary producer of the ApoE protein under physiological conditions, 
although cell profiling studies have implicated microglia as another prominent ApoE source (Zhang, et al., 
2014).  
 
While differentiation from iPS cells focused initially on creating functional human neurons, several groups 
have now also developed protocols to differentiate astrocytes from iPS cells. In spontaneously differentiating 
cultures, astrocytes will appear roughly 100 days from the time that neural progenitor cells are placed in 
differentiation media (Shi, et al., 2012). To obtain faster cultures with a higher purity of astrocytes, techniques 
have been developed to obtain astrocytes from gliospheres (Krencik, et al., 2011) or by directed differentiation 
via defined factors (Chen, et al., 2014). Astrocyte-like cells can also be obtained via direct reprogramming of 
fibroblast cells (Caiazzo, et al., 2015). The admirable plasticity of these glial cells, however, which make them 
such an important and adaptable cell in the brain, has historically led to issues of how representative primary 
cultured astrocytes are compared to the in vivo situation (Foo, et al., 2011; Hertz, et al., 1998; Sun, et al., 
2013). Given the different protocols in development to create iPS cell-derived human astroglia, the issue of 
variability between different groups and different cell lines is likely to require a concerted effort by the entire 
neural iPS cell community to address this issue. 
 
Microglia 
Microglia are complex and dynamic cells responding to their environment by releasing chemical transmitters 
as well as phagocytize cell debris, synapses, or whole cells. Both pro-inflammatory and neuroprotective roles 
for microglia have been demonstrated in AD. Local resident microglia become activated and rapidly react to 
amyloid plaque formation by extending processes, migrating toward plaques, and aggregate around them 
(Bolmont, et al., 2008; Lue, et al., 2001). Also, microglia are demonstrated to undergo apoptosis in AD brain 
(Lassmann, et al., 1995; Sugaya, et al., 1997; Yang, et al., 1998) and show dystrophic morphology and 
fragmentation, which could be the reason of the senescence of these cells (Streit, et al., 2009; Streit and Xue, 
2010). The differentiation of microglia from iPS cells appears possible, though perhaps more challenging than 
other neural cell types, given the unique origin of microglia (Ginhoux, et al., 2010). To date, however, 
publications only exist for creating mouse microglia (Beutner, et al., 2010; Beutner, et al., 2013; Selvaraj, et 
al., 2012; Tsuchiya, et al., 2005). We found one patent related to the “Method for obtaining human microglial 
precursor cells from pluripotent stem cells” (EP 2424976 A1) from the group of Harald Neumann (Neumann, 
2012), who also have derived microglial cells from mouse ES cells (Beutner, et al., 2010; Beutner, et al., 
2013). Another strategy was introduced by the Filgueira group, who generated microglia from human 
peripheral blood monocytes using a mixture of recombinant cytokines such as M-CSF, GM-SF, NGFβ, and 
CCL2 (Etemad, et al., 2012). Some groups have found that, in the process of making embryoid bodies and 
three-dimensional cultures, that they are able to isolate Cd11b+/CD45+ monocyte-like cells (Schwartz, et al., 
2015). However, whether these microglial precursors are representing the same characteristic as the 
microglia in vivo is a matter of debate, and our understanding of microglia and their roles in Alzheimer’s 
disease remains woefully incomplete. To date, we could not find any work in the literature that focused upon 
creating microglia from human ES or iPS cells. The production of microglia from human iPS cells is highly 
desirable, given our increasing awareness of the role of inflammation in neurodegenerative disease, and we 
look forward to seeing new protocols in the literature soon. 
 
Oligodendrocytes 
Oligodendrocytes form myelin layers around neuronal axons in order to allow high nerve conductance 
(Bercury and Macklin, 2015). White matter lesions and myelin abnormalities have been described in human 
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AD brain and mouse models (Bartzokis, 2011; Desai, et al., 2010; Desai, et al., 2009; Englund, et al., 1988; 
Kobayashi, et al., 2002; Roth, et al., 2005). The potential that iPS cell-derived oligodendrocyte precursor cells 
and mature oligodendrocytes have for both the study and treatment of demyelinating disorders has made this 
an active field, with a number of groups developing protocols. These studies have generated 
oligodendrocytes and oligodendrocytes precursors from human iPS cells either as a component of 
heterogeneous cultures (Hu, et al., 2009; Kim, et al., 2012; Swistowski, et al., 2010) or as the result of 
concerted efforts to generate these particular cell types (Douvaras, et al., 2014; Jang, et al., 2011; Ogawa, et 
al., 2011; Pouya, et al., 2011; Wang, et al., 2013). Oligodendrocytes derived from human iPS cells have been 
shown to myelinate neuronal processes in vitro (Wang, et al., 2013) and in vivo (Douvaras, et al., 2014; Major, 
et al., 2011; Pouya, et al., 2011; Wang, et al., 2013), and thus hold great promise for studying the impact of 
myelin abnormalities in AD and other demyelinating disorders. 
 
7c. Future challenges for cell type differentiation 
For each cell type differentiation, it will be crucial to eliminate remaining pluripotent iPS as well as progenitor 
cells. There are several options such as fluorescent-activated cell sorting (Sergent-Tanguy, et al., 2003) or 
magnetic separation, however they are very invasive and could potentially change the epigenetic landscape. 
It would be from advantage to have a marker of successful differentiation. (Kim, et al., 2011) showed that the 
microRNA-371-3 cluster could serve as a discrimination factor for neuronal differentiation.  
One major challenge will be to define what is a cell type and which cell type is impacted in a disease 
phenotype. To define a cell type is challenging by itself (DeFelipe, et al., 2013; Fishell and Heintz, 2013; 
Grange, et al., 2014) but solving this question will be crucial for future studies in iPS cells. This requires that 
we understand the genetic identity of a cell type, so that we can investigate strategies to specifically promote 
this cell type to differentiate from iPS cells. Once we know the genetic identity of a natural cell, we can 
correlate this identity to our engineered cell in vitro. Strategies like this are already proposed within the retina 
(Siegert, et al., 2012) . 
 
8. Modeling neurological disease in three-dimensional culture systems  
 
In the previous section, we briefly alluded to the impact of distinct cell types in AD and what are the current 
efforts in the field to generate these different neural lineages from iPS cells. Although the analysis of a pure 
cell type population can give valuable insides into the biology of the cell, it is often the interaction between 
different cell types that are most important to a true model of neural systems: for example neurons exhibit 
increased synapse formation when they are co-cultured with astrocytes (Pfrieger and Barres, 1997), and 
astrocytes may look and behave differently in two-dimensional culture than they do in the brain (Cahoy, et al., 
2008; Puschmann, et al., 2013). The latter one is a concern for all cell types, since neurons and glia both 
utilize subcellular specializations, or compartmentalization, to function properly in vivo (Khakh and McCarthy, 
2015; Tonnesen, et al., 2014). In a monolayer in a culture dish, however, some of this compartmentalization 
may be lost. One example is the observation of calcium microdomains in astrocytes in vivo and in slice 
preparations, in which specific subregions of the astrocytic arbor exhibit restricted calcium oscillations that 
may reflect activity to immediately adjacent neurons (Bernardinelli, et al., 2014; Di Castro, et al., 2011; 
Shigetomi, et al., 2013). Another concern is that phenotypes of aberrant extracellular protein aggregation are 
lost in two-dimensional cultures simply due to the lack of interstitial compartment, and metabolites of interest 
may diffuse to the media. To overcome this, recent studies have embedded human ES or iPS cell-derived 
cells in scaffolding such as hydrogel or Matrigel, to create three dimensional culture systems (Pasca, et al., 
2015; Schwartz, et al., 2015; Smith, et al., 2015). These kinds of culture systems, when created with human 
cells overexpressing fAD proteins or treated with Aβ oligomers, can recapitulate AD-like phenotypes such as 
extracellular Aβ plaque-like deposits (Choi, et al., 2014; Kim, et al., 2015) and cytoskeletal abnormalities 
(Zhang, et al., 2014).  
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To address issues that might arise from overly simplistic culture model systems, a number of groups have 
taken advantage of tissue engineering approaches that can generate either scaffolded or self-organizing 
neural cytosystems, such as  “organoids”. In 2008, the Sasai laboratory demonstrated that mouse and human 
ES cells could form self-organized apico-basally polarized cortical tissue (Eiraku and Sasai, 2012; Eiraku, et 
al., 2008). However this technique lacks the later stage of cortical development namely discrete cortical layer 
formation with the typically inside-out organization, as well as the presence of outer radial glia. (Lancaster, et 
al., 2013) improved the protocol and could model human brain development in 3D organoid structure. They 
observed cortical-like neuronal generation and organization and found astrocytes and oligodendrocytes after 
more than 100 days in vitro. To date, AD-like phenotypes have not been reported in self-organizing three-
dimensional cultures or organoids from patient-derived cells. However, the three-dimensional cultures 
reported by Choi et al., which overexpressed mutant APP, also showed an increase in phospho-Tau levels, 
suggesting that it may be possible to recapitulate many AD phenotypes within one model system, which 
would be a strong advantage in comparison to AD mouse models (Choi, et al., 2014; Kim, et al., 2015). 
Three-dimensional neural culture systems have yet to recapitulate complex in vivo brain systems that include 
elements such as the blood-brain-barrier, vascularization, or immune response, which all have an important 
impact during disease and treatment. Therefore, multiple research groups are focusing on creating 
vascularization, shown in liver tissue (Masumoto, et al., 2014; Samuel, et al., 2013; Takebe, et al., 2013) or 
blood-brain-barrier structures from iPS cells (Lippmann, et al., 2014; Lippmann, et al., 2013; Lippmann, et al., 
2012; Minami, et al., 2015).   
 
9. Conclusion 
 
In this review, we have outlined recent strategies to investigate AD pathology using human iPS cells and to 
find new therapeutic targets preventing disease onset and progression. The approval rate for AD medications 
is a scant 4% of all treatments that enter onto Phase I trials (McBride, 2012) with projections of 13.8 million 
people with AD and $1.2 trillion spent on AD-related care in the year 2050 (Association, 2013; Hebert, et al., 
2013). These numbers clearly show that new model systems are needed to better translate observations from 
rodent models into clinical studies. Human iPS cells will be an important step forward in this direction; they 
have the potential to recapitulate phenotypes from various neurological diseases in a cell type-specific 
manner.  Creating isogenic iPS cells lines overcomes problems of variability in human genomes and genome-
editing technology has become much easier to implement. We have outlined how iPS cells can model disease 
etiology, progression, and phenotypes in human AD. Several groups have, to date, succeeded in 
recapitulating multiple AD-like phenotypes in human iPS cells.  Thus, the stage appears to be set for the 
widespread use of iPS cells in preclinical drug trials for AD therapies (reviewed in (Khurana, et al., 2015)). To 
benefit most from these cellular models, it will be absolutely crucial that all experiments are performed in a 
controlled and standardized manner that will allow reproducibility between different research groups.  
 
Several areas of iPS cell research remain topics of much debate or even controversy. For example, there is 
debate over exactly how similar iPS and ES cells are, and how well iPS cells can functionally replace ES cells 
in translational research (Bock, et al., 2011; Chin, et al., 2009; Doi, et al., 2009; Hu, et al., 2010; Narsinh, et 
al., 2011; Narsinh, et al., 2011). In addition to the ethical and legal issues that have arisen regarding the 
creation of ES cells, which hinder the production of new lines, a clear advantage of iPS cells is that the donor 
is often an adult, sometimes elderly, and thus can provide a health history relevant to the disorder of interest. 
This is not possible with ES cells. This said, the ability to access patient history in the use of iPS cell research 
is highly variable between research groups and subject to a great deal of regulation to ensure patient privacy 
(King and Perrin, 2014; Lomax, et al., 2015; Lomax and Peckman, 2012; Lomax, et al., 2013).  As more and 
more iPS cell lines are characterized and this information added to public databases, we expect that even 
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researchers without direct access to patient information will benefit from these models.  The development of 
libraries of disease-associated iPS cell lines, of both genders, will allow high-throughput drug discovery and 
validation, and should make the rocky path from bench to clinic shorter and straighter.   
 
In this review, we also put a strong focus on the impact of different cell types. It will be crucial to investigate 
the impact of drugs across different cell types. The use of three-dimensional scaffolding combined with 
differentiated cells (Choi, et al., 2014), or the creation of self-organizing neural tissue structures in vitro 
(Eiraku and Sasai, 2012; Eiraku, et al., 2008; Kadoshima, et al., 2013; Lancaster, et al., 2013; Lancaster and 
Knoblich, 2014), hold great promise for modeling the intricate micro- and macro-environment of the brain. In 
the future, it may be possible to screen drugs in these cytosystems, which have the benefit of containing 
multiple neural cell types in a physiological microenvironment and, with the development of vascularization 
technique, may include blood-brain barrier penetration in the assay at an early stage of drug discovery. 
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Figure 1. Using human patient derived induced pluripotent stem (iPS) cells to model Alzheimer’s 
disease (AD) pathology. This model figure illustrates the logical path of experiments using iPS cells to study 
AD phenotypes and screen for novel therapeutics. Somatic cells (etc. blood, skin) are reprogrammed in vitro 
into iPS cell colonies. At this point, or later, genome-editing techniques can be used to create isogenic lines 
containing specific mutations or transgenes. Techniques exist to differentiate the iPS cells into neural cells 
that include neurons, microglia, astrocytes and oligodendrocytes, as well as neural progenitor cells (not 
pictured). From the iPS cell stage, self-organizing tissue cytosystems, or organoids, can also be created in 
three-dimensional culture. Neural cells differentiated from iPS lines with sporadic or familial AD (sAD or fAD) 
backgrounds can display a number of AD-like phenotypes that can be assayed in vitro. These include amyloid 
β peptide production and, in the case of three-dimensional culture, amyloid plaques, tau pathology, synaptic 
dysfunction, immune activation, genomic instability, and aberrant endosome trafficking. High-throughput 
screens can be designed to examine the impact of small molecule or other treatments upon these and other 
AD-like phenotypes directly in human neural cells. The development of novel treatments for the AD patient 
and the success of these treatments in the clinic completes the cycle. 
 
10. References 
 
(2013) Strengthening connections between Down syndrome and AD. Lancet Neurol 12:931. doi: 
10.1016/S1474-4422(13)70228-X. PMID: 24050729 
Alzheimer, A (1911) Über eigenartige Krankheitsfalle des späteren Alters. Zbl. ges. Neurol. Psych. 4:356-385.  
Ando, K, Brion, JP, Stygelbout, V, Suain, V, Authelet, M, Dedecker, R, Chanut, A, Lacor, P, Lavaur, J, 
Sazdovitch, V, Rogaeva, E, Potier, MC and Duyckaerts, C (2013) Clathrin adaptor CALM/PICALM is 
associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathol 125:861-
78. doi: 10.1007/s00401-013-1111-z. PMID: 23589030 
Antunez, C, Boada, M, Gonzalez-Perez, A, Gayan, J, Ramirez-Lorca, R, Marin, J, Hernandez, I, Moreno-Rey, 
C, Moron, FJ, Lopez-Arrieta, J, Mauleon, A, Rosende-Roca, M, Noguera-Perea, F, Legaz-Garcia, A, 
Vivancos-Moreau, L, Velasco, J, Carrasco, JM, Alegret, M, Antequera-Torres, M, Manzanares, S, 
Romo, A, Blanca, I, Ruiz, S, Espinosa, A, Castano, S, Garcia, B, Martinez-Herrada, B, Vinyes, G, 
Lafuente, A, Becker, JT, Galan, JJ, Serrano-Rios, M, Alzheimer's Disease Neuroimaging, I, Vazquez, 
E, Tarraga, L, Saez, ME, Lopez, OL, Real, LM and Ruiz, A (2011) The membrane-spanning 4-
domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's 
disease. Genome Med 3:33. doi: 10.1186/gm249. PMID: 21627779 
Association, A (2013) 2013 Alzheimer's disease facts and figures. Alzheimer's & dementia : the journal of the 
Alzheimer's Association 8:131-68. doi: 10.1016/j.jalz.2012.02.001. PMID: 22404854 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
15 
Ballatore, C, Lee, VMY and Trojanowski, JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease 
and related disorders. Nature Reviews Neuroscience 8:663-672.  
Bartos, M, Vida, I and Jonas, P (2007) Synaptic mechanisms of synchronized gamma oscillations in inhibitory 
interneuron networks. Nat Rev Neurosci 8:45-56. doi: 10.1038/nrn2044. PMID: 17180162 
Bartzokis, G (2011) Alzheimer's disease as homeostatic responses to age-related myelin breakdown. 
Neurobiol Aging 32:1341-71. doi: 10.1016/j.neurobiolaging.2009.08.007. PMID: 19775776 
Bercury, KK and Macklin, WB (2015) Dynamics and mechanisms of CNS myelination. Dev Cell 32:447-58. 
doi: 10.1016/j.devcel.2015.01.016. PMID: 25710531 
Bernardinelli, Y, Randall, J, Janett, E, Nikonenko, I, Konig, S, Jones, EV, Flores, CE, Murai, KK, Bochet, CG, 
Holtmaat, A and Muller, D (2014) Activity-dependent structural plasticity of perisynaptic astrocytic 
domains promotes excitatory synapse stability. Curr Biol 24:1679-88. doi: 10.1016/j.cub.2014.06.025. 
PMID: 25042585 
Bertram, L, Lange, C, Mullin, K, Parkinson, M, Hsiao, M, Hogan, MF, Schjeide, BM, Hooli, B, Divito, J, Ionita, 
I, Jiang, H, Laird, N, Moscarillo, T, Ohlsen, KL, Elliott, K, Wang, X, Hu-Lince, D, Ryder, M, Murphy, A, 
Wagner, SL, Blacker, D, Becker, KD and Tanzi, RE (2008) Genome-wide association analysis reveals 
putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83:623-32. doi: 
10.1016/j.ajhg.2008.10.008. PMID: 18976728 
Bertram, L, McQueen, MB, Mullin, K, Blacker, D and Tanzi, RE (2007) Systematic meta-analyses of 
Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39:17-23. doi: 
10.1038/ng1934. PMID: 17192785 
Bertram, L and Tanzi, RE (2008) Thirty years of Alzheimer's disease genetics: The implications of systematic 
meta-analyses. Nature Reviews Neuroscience 9:768-778.  
Beutner, C, Roy, K, Linnartz, B, Napoli, I and Neumann, H (2010) Generation of microglial cells from mouse 
embryonic stem cells. Nat Protoc 5:1481-94. doi: 10.1038/nprot.2010.90. PMID: 20725065 
Beutner, C, Linnartz-Gerlach, B, Schmidt, SV, Beyer, M, Mallmann, MR, Staratschek-Jox, A, Schultze, JL and 
Neumann, H (2013) Unique transcriptome signature of mouse microglia. Glia 61:1429-42. doi: 
10.1002/glia.22524. PMID: 23832717 
Beyreuther, K, Pollwein, P, Multhaup, G, Monning, U, Konig, G, Dyrks, T, Schubert, W and Masters, CL 
(1993) Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, 
disease, and Down's syndrome. Ann N Y Acad Sci 695:91-102. PMID: 8239320 
Blalock, EM, Buechel, HM, Popovic, J, Geddes, JW and Landfield, PW (2011) Microarray analyses of laser-
captured hippocampus reveal distinct gray and white matter signatures associated with incipient 
Alzheimer's disease. Journal of chemical neuroanatomy 42:118-26. doi: 
10.1016/j.jchemneu.2011.06.007. PMID: 21756998 
Blalock, EM, Geddes, JW, Chen, KC, Porter, NM, Markesbery, WR and Landfield, PW (2004) Incipient 
Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor 
suppressor responses. Proc Natl Acad Sci U S A 101:2173-8. doi: 10.1073/pnas.0308512100. PMID: 
14769913 
Blennow, K (2010) Biomarkers in Alzheimer's disease drug development. Nat Med 16:1218-22. doi: 
10.1038/nm.2221. PMID: 21052077 
Blondel, S, Jaskowiak, AL, Egesipe, AL, Le Corf, A, Navarro, C, Cordette, V, Martinat, C, Laabi, Y, Djabali, K, 
de Sandre-Giovannoli, A, Levy, N, Peschanski, M and Nissan, X (2014) Induced pluripotent stem cells 
reveal functional differences between drugs currently investigated in patients with hutchinson-gilford 
progeria syndrome. Stem Cells Transl Med 3:510-9. doi: 10.5966/sctm.2013-0168. PMID: 24598781 
Bock, C, Kiskinis, E, Verstappen, G, Gu, H, Boulting, G, Smith, ZD, Ziller, M, Croft, GF, Amoroso, MW, 
Oakley, DH, Gnirke, A, Eggan, K and Meissner, A (2011) Reference Maps of human ES and iPS cell 
variation enable high-throughput characterization of pluripotent cell lines. Cell 144:439-52. doi: 
10.1016/j.cell.2010.12.032. PMID: 21295703 
Bolmont, T, Haiss, F, Eicke, D, Radde, R, Mathis, CA, Klunk, WE, Kohsaka, S, Jucker, M and Calhoun, ME 
(2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. Journal of 
Neuroscience 28:4283-4292. doi: 10.1523/jneurosci.4814-07.2008. PMID: 18417708 
Boulting, GL, Kiskinis, E, Croft, GF, Amoroso, MW, Oakley, DH, Wainger, BJ, Williams, DJ, Kahler, DJ, 
Yamaki, M, Davidow, L, Rodolfa, CT, Dimos, JT, Mikkilineni, S, MacDermott, AB, Woolf, CJ, 
Henderson, CE, Wichterle, H and Eggan, K (2011) A functionally characterized test set of human 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
induced pluripotent stem cells. Nature Biotechnology 29:279-U147. doi: 10.1038/nbt.1783. PMID: 
21293464 
Bouwman, BA and de Laat, W (2015) Architectural hallmarks of the pluripotent genome. FEBS Lett. doi: 
10.1016/j.febslet.2015.04.055. PMID: 25957773 
Braak, H and Braak, E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 
82:239-59. PMID: 1759558 
Bradshaw, EM, Chibnik, LB, Keenan, BT, Ottoboni, L, Raj, T, Tang, A, Rosenkrantz, LL, Imboywa, S, Lee, M, 
Von Korff, A, Morris, MC, Evans, DA, Johnson, K, Sperling, RA, Schneider, JA, Bennett, DA and De 
Jager, PL (2013) CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. 
Nature Neuroscience 16:848-850. doi: papers2://publication/doi/10.1038/nn.3435.  
Brennand, KJ, Simone, A, Jou, J, Gelboin-Burkhart, C, Tran, N, Sangar, S, Li, Y, Mu, Y, Chen, G, Yu, D, 
McCarthy, S, Sebat, J and Gage, FH (2011) Modelling schizophrenia using human induced pluripotent 
stem cells. Nature 473:221-+. doi: 10.1038/nature09915. PMID: 21490598 
Bribian, A, Figueres-Onate, M, Martin-Lopez, E and Lopez-Mascaraque, L (2015) Decoding astrocyte 
heterogeneity: New tools for clonal analysis. Neuroscience. doi: 10.1016/j.neuroscience.2015.04.036. 
PMID: 25917835 
Broccoli, V, Rubio, A, Taverna, S and Yekhlef, L (2015) Overcoming the hurdles for a reproducible generation 
of human functionally mature reprogrammed neurons. Exp Biol Med (Maywood) 240:787-94. doi: 
10.1177/1535370215577585. PMID: 25790823 
Broccoli, V, Giannelli, SG and Mazzara, PG (2014) Modeling physiological and pathological human 
neurogenesis in the dish. Front Neurosci 8:183. doi: 10.3389/fnins.2014.00183. PMID: 25104921 
Bu, G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. 
Nat Rev Neurosci 10:333-44. doi: 10.1038/nrn2620. PMID: 19339974 
Burger, PC and Vogel, FS (1973) The development of the pathologic changes of Alzheimer's disease and 
senile dementia in patients with Down's syndrome. Am J Pathol 73:457-76. PMID: 4271339 
Byrne, SM, Mali, P and Church, GM (2014) Genome editing in human stem cells. Methods Enzymol 546:119-
38. doi: 10.1016/B978-0-12-801185-0.00006-4. PMID: 25398338 
Cahoy, JD, Emery, B, Kaushal, A, Foo, LC, Zamanian, JL, Christopherson, KS, Xing, Y, Lubischer, JL, Krieg, 
PA, Krupenko, SA, Thompson, WJ and Barres, BA (2008) A transcriptome database for astrocytes, 
neurons, and oligodendrocytes: a new resource for understanding brain development and function. J 
Neurosci 28:264-78. doi: 10.1523/JNEUROSCI.4178-07.2008. PMID: 18171944 
Caiazzo, M, Giannelli, S, Valente, P, Lignani, G, Carissimo, A, Sessa, A, Colasante, G, Bartolomeo, R, 
Massimino, L, Ferroni, S, Settembre, C, Benfenati, F and Broccoli, V (2015) Direct conversion of 
fibroblasts into functional astrocytes by defined transcription factors. Stem Cell Reports 4:25-36. doi: 
10.1016/j.stemcr.2014.12.002. PMID: 25556566 
Calero, M, Rostagno, A, Matsubara, E, Zlokovic, B, Frangione, B and Ghiso, J (2000) Apolipoprotein J 
(clusterin) and Alzheimer's disease. Microsc Res Tech 50:305-15. doi: 10.1002/1097-
0029(20000815)50:4<305::AID-JEMT10>3.0.CO;2-L. PMID: 10936885 
Carroll, D (2011) Genome Engineering With Zinc-Finger Nucleases. Genetics 188:773-782. doi: 
10.1534/genetics.111.131433. PMID: 21828278 
Castellano, JM, Kim, J, Stewart, FR, Jiang, H, DeMattos, RB, Patterson, BW, Fagan, AM, Morris, JC, 
Mawuenyega, KG, Cruchaga, C, Goate, AM, Bales, KR, Paul, SM, Bateman, RJ and Holtzman, DM 
(2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Science 
Translational Medicine 3.  
Cataldo, A, Rebeck, GW, Ghetri, B, Hulette, C, Lippa, C, Van Broeckhoven, C, van Duijn, C, Cras, P, 
Bogdanovic, N, Bird, T, Peterhoff, C and Nixon, R (2001) Endocytic disturbances distinguish among 
subtypes of Alzheimer's disease and related disorders. Ann Neurol 50:661-5. PMID: 11706973 
Cataldo, AM, Peterhoff, CM, Troncoso, JC, Gomez-Isla, T, Hyman, BT and Nixon, RA (2000) Endocytic 
pathway abnormalities precede amyloid β deposition in sporadic alzheimer's disease and down 
syndrome: Differential effects of APOE genotype and presenilin mutations. American Journal Of 
Pathology 157:277-286.  
Cataldo, AM, Mathews, PM, Boiteau, AB, Hassinger, LC, Peterhoff, CM, Jiang, Y, Mullaney, K, Neve, RL, 
Gruenberg, J and Nixon, RA (2008) Down syndrome fibroblast model of Alzheimer-related endosome 
pathology: accelerated endocytosis promotes late endocytic defects. Am J Pathol 173:370-84. doi: 
10.2353/ajpath.2008.071053. PMID: 18535180 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
Chang, CY, Chen, SM, Lu, HE, Lai, SM, Lai, PS, Shen, PW, Chen, PY, Shen, CI, Harn, HJ, Lin, SZ, Hwang, 
SM and Su, HL (2015) N-butylidenephthalide Attenuates Alzheimer's Disease-Like Cytopathy in Down 
Syndrome Induced Pluripotent Stem Cell-Derived Neurons. Sci Rep 5:8744. doi: 10.1038/srep08744. 
PMID: 25735452 
Chen, C, Jiang, P, Xue, H, Peterson, SE, Tran, HT, McCann, AE, Parast, MM, Li, S, Pleasure, DE, Laurent, 
LC, Loring, JF, Liu, Y and Deng, W (2014) Role of astroglia in Down's syndrome revealed by patient-
derived human-induced pluripotent stem cells. Nat Commun 5:4430. doi: 10.1038/ncomms5430. 
PMID: 25034944 
Chiba, K and Hockemeyer, D (2015) Genome Editing in Human Pluripotent Stem Cells Using Site-Specific 
Nucleases. Chromosomal Mutagenesis, Second Edition 1239:267-280. doi: 10.1007/978-1-4939-
1862-1_15. PMID: 25408412 
Chin, MH, Mason, MJ, Xie, W, Volinia, S, Singer, M, Peterson, C, Ambartsumyan, G, Aimiuwu, O, Richter, L, 
Zhang, J, Khvorostov, I, Ott, V, Grunstein, M, Lavon, N, Benvenisty, N, Croce, CM, Clark, AT, Baxter, 
T, Pyle, AD, Teitell, MA, Pelegrini, M, Plath, K and Lowry, WE (2009) Induced pluripotent stem cells 
and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 5:111-23. 
doi: S1934-5909(09)00292-6 [pii] 
10.1016/j.stem.2009.06.008. PMID: 19570518 
Chinchalongporn, V, Koppensteiner, P, Pre, D, Thangnipon, W, Bilo, L and Arancio, O (2015) Connectivity 
and circuitry in a dish versus in a brain. Alzheimers Res Ther 7:44. doi: 10.1186/s13195-015-0129-y. 
PMID: 26045718 
Choi, SH, Kim, YH, Hebisch, M, Sliwinski, C, Lee, S, D'Avanzo, C, Chen, H, Hooli, B, Asselin, C, Muffat, J, 
Klee, JB, Zhang, C, Wainger, BJ, Peitz, M, Kovacs, DM, Woolf, CJ, Wagner, SL, Tanzi, RE and Kim, 
DY (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 
515:274-8. doi: 10.1038/nature13800. PMID: 25307057 
Chung, CY, Khurana, V, Auluck, PK, Tardiff, DF, Mazzulli, JR, Soldner, F, Baru, V, Lou, Y, Freyzon, Y, Cho, 
S, Mungenast, AE, Muffat, J, Mitalipova, M, Pluth, MD, Jui, NT, Schule, B, Lippard, SJ, Tsai, LH, 
Krainc, D, Buchwald, SL, Jaenisch, R and Lindquist, S (2013) Identification and rescue of alpha-
synuclein toxicity in Parkinson patient-derived neurons. Science 342:983-7. doi: 
10.1126/science.1245296. PMID: 24158904 
Consortium, HDi (2012) Induced pluripotent stem cells from patients with Huntington's disease show CAG-
repeat-expansion-associated phenotypes. Cell Stem Cell 11:264-78. doi: 10.1016/j.stem.2012.04.027. 
PMID: 22748968 
Corder, EH, Saunders, AM, Strittmatter, WJ, Schmechel, DE, Gaskell, PC, Small, GW, Roses, AD, Haines, JL 
and Pericak-Vance, MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's 
disease in late onset families. Science 261:921-923.  
Corneveaux, JJ, Myers, AJ, Allen, AN, Pruzin, JJ, Ramirez, M, Engel, A, Nalls, MA, Chen, K, Lee, W, 
Chewning, K, Villa, SE, Meechoovet, HB, Gerber, JD, Frost, D, Benson, HL, O'Reilly, S, Chibnik, LB, 
Shulman, JM, Singleton, AB, Craig, DW, Van Keuren-Jensen, KR, Dunckley, T, Bennett, DA, De 
Jager, PL, Heward, C, Hardy, J, Reiman, EM and Huentelman, MJ (2010) Association of CR1, CLU 
and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically 
verified individuals. Hum Mol Genet 19:3295-301. doi: 10.1093/hmg/ddq221. PMID: 20534741 
Cowan, CA, Atienza, J, Melton, DA and Eggan, K (2005) Nuclear reprogramming of somatic cells after fusion 
with human embryonic stem cells. Science 309:1369-1373. doi: 10.1126/science.1116447. PMID: 
16123299 
Crehan, H, Hardy, J and Pocock, J (2013) Blockage of CR1 prevents activation of rodent microglia. Neurobiol 
Dis 54:139-49. doi: 10.1016/j.nbd.2013.02.003. PMID: 23454195 
Dabir, DV, Robinson, MB, Swanson, E, Zhang, B, Trojanowski, JQ, Lee, VM and Forman, MS (2006) 
Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci 26:644-54. 
doi: 10.1523/JNEUROSCI.3861-05.2006. PMID: 16407562 
De Strooper, B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease 
process. Physiol Rev 90:465-94. doi: 10.1152/physrev.00023.2009. PMID: 20393191 
DeFelipe, J, Lopez-Cruz, PL, Benavides-Piccione, R, Bielza, C, Larranaga, P, Anderson, S, Burkhalter, A, 
Cauli, B, Fairen, A, Feldmeyer, D, Fishell, G, Fitzpatrick, D, Freund, TF, Gonzalez-Burgos, G, Hestrin, 
S, Hill, S, Hof, PR, Huang, J, Jones, EG, Kawaguchi, Y, Kisvarday, Z, Kubota, Y, Lewis, DA, Marin, O, 
Markram, H, McBain, CJ, Meyer, HS, Monyer, H, Nelson, SB, Rockland, K, Rossier, J, Rubenstein, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
JLR, Rudy, B, Scanziani, M, Shepherd, GM, Sherwood, CC, Staiger, JF, Tamas, G, Thomson, A, 
Wang, Y, Yuste, R and Ascoli, GA (2013) New insights into the classification and nomenclature of 
cortical GABAergic interneurons. Nature Reviews Neuroscience 14:202-216. doi: 10.1038/nrn3444. 
PMID: 23385869 
Deng, YL, Liu, LH, Wang, Y, Tang, HD, Ren, RJ, Xu, W, Ma, JF, Wang, LL, Zhuang, JP, Wang, G and Chen, 
SD (2012) The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's 
disease. Hum Genet 131:1245-9. doi: 10.1007/s00439-012-1154-6. PMID: 22382309 
Denham, M and Dottori, M (2011) Neural Differentiation of Induced Pluripotent Stem Cells. 
Neurodegeneration: Methods and Protocols 793:99-110. doi: 10.1007/978-1-61779-328-8_7. PMID: 
21913096 
Desai, MK, Mastrangelo, MA, Ryan, DA, Sudol, KL, Narrow, WC and Bowers, WJ (2010) Early 
oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. 
Am J Pathol 177:1422-35. doi: 10.2353/ajpath.2010.100087. PMID: 20696774 
Desai, MK, Sudol, KL, Janelsins, MC, Mastrangelo, MA, Frazer, ME and Bowers, WJ (2009) Triple-transgenic 
Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to 
appearance of amyloid and tau pathology. Glia 57:54-65. doi: 10.1002/glia.20734. PMID: 18661556 
Di Castro, MA, Chuquet, J, Liaudet, N, Bhaukaurally, K, Santello, M, Bouvier, D, Tiret, P and Volterra, A 
(2011) Local Ca2+ detection and modulation of synaptic release by astrocytes. Nat Neurosci 14:1276-
84. doi: 10.1038/nn.2929. PMID: 21909085 
Dimos, JT, Rodolfa, KT, Niakan, KK, Weisenthal, LM, Mitsumoto, H, Chung, W, Croft, GF, Saphier, G, Leibel, 
R, Goland, R, Wichterle, H, Henderson, CE and Eggan, K (2008) Induced pluripotent stem cells 
generated from patients with ALS can be differentiated into motor neurons. Science 321:1218-21. doi: 
1158799 [pii] 
10.1126/science.1158799. PMID: 18669821 
Ding, Q, Regan, SN, Xia, Y, Oostrom, LA, Cowan, CA and Musunuru, K (2013) Enhanced Efficiency of 
Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRs. Cell Stem 
Cell 12:393-394. doi: 10.1016/j.stem.2013.03.006. PMID: 23561441 
Ding, Q, Lee, Y-K, Schaefer, EAK, Peters, DT, Veres, A, Kim, K, Kuperwasser, N, Motola, DL, Meissner, TB, 
Hendriks, WT, Trevisan, M, Gupta, RM, Moisan, A, Banks, E, Friesen, M, Schinzel, RT, Xia, F, Tang, 
A, Xia, Y, Figueroa, E, Wann, A, Ahfeldt, T, Daheron, L, Zhang, F, Rubin, LL, Peng, LF, Chung, RT, 
Musunuru, K and Cowan, CA (2013) A TALEN Genome-Editing System for Generating Human Stem 
Cell-Based Disease Models. Cell Stem Cell 12:238-251. doi: 10.1016/j.stem.2012.11.011. PMID: 
23246482 
Dobbin, MM, Madabhushi, R, Pan, L, Chen, Y, Kim, D, Gao, J, Ahononu, B, Pao, PC, Qiu, Y, Zhao, Y and 
Tsai, LH (2013) SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. 
Nat Neurosci. doi: nn.3460 [pii] 
10.1038/nn.3460. PMID: 23852118 
Doi, A, Park, IH, Wen, B, Murakami, P, Aryee, MJ, Irizarry, R, Herb, B, Ladd-Acosta, C, Rho, J, Loewer, S, 
Miller, J, Schlaeger, T, Daley, GQ and Feinberg, AP (2009) Differential methylation of tissue- and 
cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic 
stem cells and fibroblasts. Nat Genet 41:1350-3. doi: ng.471 [pii] 
10.1038/ng.471. PMID: 19881528 
Doody, RS, Raman, R, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, Kieburtz, K, He, F, Sun, X, Thomas, RG, 
Aisen, PS, Alzheimer's Disease Cooperative Study Steering, C, Siemers, E, Sethuraman, G, Mohs, R 
and Semagacestat Study, G (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's 
disease. N Engl J Med 369:341-50. doi: 10.1056/NEJMoa1210951. PMID: 23883379 
Doody, RS, Thomas, RG, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, Kieburtz, K, Raman, R, Sun, X, Aisen, 
PS, Siemers, E, Liu-Seifert, H, Mohs, R, Alzheimer's Disease Cooperative Study Steering, C and 
Solanezumab Study, G (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's 
disease. N Engl J Med 370:311-21. doi: 10.1056/NEJMoa1312889. PMID: 24450890 
Douvaras, P, Wang, J, Zimmer, M, Hanchuk, S, O'Bara, MA, Sadiq, S, Sim, FJ, Goldman, J and Fossati, V 
(2014) Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis 
patients by induced pluripotent stem cells. Stem Cell Reports 3:250-9. doi: 
10.1016/j.stemcr.2014.06.012. PMID: 25254339 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
Ebert, AD, Yu, J, Rose, FF, Jr., Mattis, VB, Lorson, CL, Thomson, JA and Svendsen, CN (2009) Induced 
pluripotent stem cells from a spinal muscular atrophy patient. Nature 457:277-80. doi: nature07677 
[pii] 10.1038/nature07677. PMID: 19098894 
Eiraku, M and Sasai, Y (2012) Self-formation of layered neural structures in three-dimensional culture of ES 
cells. Curr Opin Neurobiol 22:768-77. doi: 10.1016/j.conb.2012.02.005. PMID: 22405989 
Eiraku, M, Watanabe, K, Matsuo-Takasaki, M, Kawada, M, Yonemura, S, Matsumura, M, Wataya, T, 
Nishiyama, A, Muguruma, K and Sasai, Y (2008) Self-organized formation of polarized cortical tissues 
from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 3:519-32. doi: 
10.1016/j.stem.2008.09.002. PMID: 18983967 
Englund, E, Brun, A and Alling, C (1988) White matter changes in dementia of Alzheimer's type. Biochemical 
and neuropathological correlates. Brain 111 ( Pt 6):1425-39. PMID: 3208064 
Espuny-Camacho, I, Michelsen, KA, Gall, D, Linaro, D, Hasche, A, Bonnefont, J, Bali, C, Orduz, D, Bilheu, A, 
Herpoel, A, Lambert, N, Gaspard, N, Peron, S, Schiffmann, SN, Giugliano, M, Gaillard, A and 
Vanderhaeghen, P (2013) Pyramidal neurons derived from human pluripotent stem cells integrate 
efficiently into mouse brain circuits in vivo. Neuron 77:440-56. doi: 10.1016/j.neuron.2012.12.011. 
PMID: 23395372 
Etemad, S, Zamin, RM, Ruitenberg, MJ and Filgueira, L (2012) A novel in vitro human microglia model: 
characterization of human monocyte-derived microglia. J Neurosci Methods 209:79-89. doi: 
10.1016/j.jneumeth.2012.05.025. PMID: 22659341 
Evans, MJ and Kaufman, MH (1981) Establishment in Culture of Pluripotential Cells from Mouse Embryos. 
Nature 292:154-156. doi: 10.1038/292154a0. PMID: 7242681 
Farrer, LA, Cupples La Fau - Haines, JL, Haines Jl Fau - Hyman, B, Hyman B Fau - Kukull, WA, Kukull Wa 
Fau - Mayeux, R, Mayeux R Fau - Myers, RH, Myers Rh Fau - Pericak-Vance, MA, Pericak-Vance Ma 
Fau - Risch, N, Risch N Fau - van Duijn, CM and van Duijn, CM (1997) Effects of age, sex, and 
ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-
analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. PMID: 9343467 
Fischer, A, Sananbenesi, F, Pang, PT, Lu, B and Tsai, LH (2005) Opposing roles of transient and prolonged 
expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48:825-838.  
Fishell, G and Heintz, N (2013) The Neuron Identity Problem: Form Meets Function. Neuron 80:602-612. doi: 
10.1016/j.neuron.2013.10.035. PMID: 24183013 
Fong, H, Wang, C, Knoferle, J, Walker, D, Balestra, ME, Tong, LM, Leung, L, Ring, KL, Seeley, WW, 
Karydas, A, Kshirsagar, MA, Boxer, AL, Kosik, KS, Miller, BL and Huang, Y (2013) Genetic correction 
of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell 
Reports 1:226-34. doi: 10.1016/j.stemcr.2013.08.001. PMID: 24319659 
Foo, LC, Allen, NJ, Bushong, EA, Ventura, PB, Chung, WS, Zhou, L, Cahoy, JD, Daneman, R, Zong, H, 
Ellisman, MH and Barres, BA (2011) Development of a method for the purification and culture of 
rodent astrocytes. Neuron 71:799-811. doi: 10.1016/j.neuron.2011.07.022. PMID: 21903074 
Fryer, JD, Simmons, K, Parsadanian, M, Bales, KR, Paul, SM, Sullivan, PM and Holtzman, DM (2005) Human 
apolipoprotein E4 alters the amyloid-β 40:42 ratio and promotes the formation of cerebral amyloid 
angiopathy in an amyloid precursor protein transgenic model. Journal of Neuroscience 25:2803-2810.  
Gatz, M, Reynolds, CA, Fratiglioni, L, Johansson, B, Mortimer, JA, Berg, S, Fiske, A and Pedersen, NL (2006) 
Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63:168-74. 
doi: 10.1001/archpsyc.63.2.168. PMID: 16461860 
Ginhoux, F, Greter, M, Leboeuf, M, Nandi, S, See, P, Gokhan, S, Mehler, MF, Conway, SJ, Ng, LG, Stanley, 
ER, Samokhvalov, IM and Merad, M (2010) Fate mapping analysis reveals that adult microglia derive 
from primitive macrophages. Science 330:841-845. PMID: 20966214 
Gjoneska, E, Pfenning, AR, Mathys, H, Quon, G, Kundaje, A, Tsai, LH and Kellis, M (2015) Conserved 
epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 518:365-
9. doi: 10.1038/nature14252. PMID: 25693568 
Glenner, GG and Wong, CW (1984) Alzheimer's disease: Initial report of the purification and characterization 
of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 
120:885-890.  
Goate, A, Chartier-Harlin, M-C, Mullan, M, Brown, J, Crawford, F, Fidani, L, Giuffra, L, Haynes, A, Irving, N, 
James, L, Mant, R, Newton, P, Rooke, K, Roques, P, Talbot, C, Pericak-Vance, M, Roses, A, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
Williamson, R, Rossor, M, Owen, M and Hardy, J (1991) Segregation of a missense mutation in the 
amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.  
Goate, A (2006) Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial 
Alzheimer's disease. J Alzheimers Dis 9:341-7. PMID: 16914872 
Goldgaber, D, Lerman, MI, McBride, WO, Saffiotti, U and Gajdusek, DC (1987) Isolation, characterization, 
and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of 
brain in Alzheimer's disease, Down's syndrome and aging. J Neural Transm Suppl 24:23-8. PMID: 
2960782 
Goto, M (1997) Hierarchical deterioration of body systems in Werner's syndrome: Implications for normal 
ageing. Mechanisms of Ageing and Development 98:239-254.  
Götz, J, Deters, N, Doldissen, A, Bokhari, L, Ke, Y, Wiesner, A, Schonrock, N and Ittner, LM (2007) A Decade 
of Tau Transgenic Animal Models and Beyond. Brain Pathology 17:91-103. doi: 10.1111/j.1750-
3639.2007.00051.x.  
Graeber, MB, Kosel, S, Egensperger, R, Banati, RB, Muller, U, Bise, K, Hoff, P, Moller, HJ, Fujisawa, K and 
Mehraein, P (1997) Rediscovery of the case described by Alois Alzheimer in 1911: historical, 
histological and molecular genetic analysis. Neurogenetics 1:73-80. PMID: 10735278 
Grange, P, Bohland, JW, Okaty, BW, Sugino, K, Bokil, H, Nelson, SB, Ng, L, Hawrylycz, M and Mitra, PP 
(2014) Cell-type-based model explaining coexpression patterns of genes in the brain. Proceedings of 
the National Academy of Sciences of the United States of America 111:5397-5402. doi: 
10.1073/pnas.1312098111. PMID: 24706869 
Grundke-Iqbal, I, Iqbal, K, Quinlan, M, Tung, YC, Zaidi, MS and Wisniewski, HM (1986) Microtubule-
associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261:6084-9. 
PMID: 3084478 
Guerreiro, R, Wojtas, A, Bras, J, Carrasquillo, M, Rogaeva, E, Majounie, E, Cruchaga, C, Sassi, C, Kauwe, 
JS, Younkin, S, Hazrati, L, Collinge, J, Pocock, J, Lashley, T, Williams, J, Lambert, JC, Amouyel, P, 
Goate, A, Rademakers, R, Morgan, K, Powell, J, St George-Hyslop, P, Singleton, A, Hardy, J and 
Alzheimer Genetic Analysis, G (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368:117-
27. doi: 10.1056/NEJMoa1211851. PMID: 23150934 
Hanna, JH, Saha, K and Jaenisch, R (2010) Pluripotency and Cellular Reprogramming: Facts, Hypotheses, 
Unresolved Issues. Cell 143:508-525. doi: 10.1016/j.cell.2010.10.008. PMID: 21074044 
Harold, D, Abraham, R, Hollingworth, P, Sims, R, Gerrish, A, Hamshere, ML, Pahwa, JS, Moskvina, V, 
Dowzell, K, Williams, A, Jones, N, Thomas, C, Stretton, A, Morgan, AR, Lovestone, S, Powell, J, 
Proitsi, P, Lupton, MK, Brayne, C, Rubinsztein, DC, Gill, M, Lawlor, B, Lynch, A, Morgan, K, Brown, 
KS, Passmore, PA, Craig, D, McGuinness, B, Todd, S, Holmes, C, Mann, D, Smith, AD, Love, S, 
Kehoe, PG, Hardy, J, Mead, S, Fox, N, Rossor, M, Collinge, J, Maier, W, Jessen, F, Schurmann, B, 
van den Bussche, H, Heuser, I, Kornhuber, J, Wiltfang, J, Dichgans, M, Frolich, L, Hampel, H, Hull, M, 
Rujescu, D, Goate, AM, Kauwe, JSK, Cruchaga, C, Nowotny, P, Morris, JC, Mayo, K, Sleegers, K, 
Bettens, K, Engelborghs, S, De Deyn, PP, Van Broeckhoven, C, Livingston, G, Bass, NJ, Gurling, H, 
McQuillin, A, Gwilliam, R, Deloukas, P, Al-Chalabi, A, Shaw, CE, Tsolaki, M, Singleton, AB, Guerreiro, 
R, Muhleisen, TW, Nothen, MM, Moebus, S, Jockel, K-H, Klopp, N, Wichmann, HE, Carrasquillo, MM, 
Pankratz, VS, Younkin, SG, Holmans, PA, O'Donovan, M, Owen, MJ and Williams, J (2009) Genome-
wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. 
Nat Genet 41:1088-1093. doi: http://www.nature.com/ng/journal/v41/n10/suppinfo/ng.440_S1.html.  
Hasty, P, Campisi, J, Hoeijmakers, J, van Steeg, H and Vijg, J (2003) Aging and Genome Maintenance: 
Lessons from the Mouse? Science 299:1355-1359. doi: 10.1126/science.1079161.  
Haydon, PG and Nedergaard, M (2015) How do astrocytes participate in neural plasticity? Cold Spring Harb 
Perspect Biol 7:a020438. doi: 10.1101/cshperspect.a020438. PMID: 25502516 
Hazra, A, Gu, F, Aulakh, A, Berridge, C, Eriksen, JL and Ziburkus, J (2013) Inhibitory neuron and 
hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. PLoS One 8:e64318. 
doi: 10.1371/journal.pone.0064318. PMID: 23691195 
Hebert, LE, Weuve, J, Scherr, Pa and Evans, Da (2013) Alzheimer disease in the United States (2010-2050) 
estimated using the 2010 census. Neurology. doi: 10.1212/WNL.0b013e31828726f5. PMID: 23390181 
Hertz, L, Peng, L and Lai, JC (1998) Functional studies in cultured astrocytes. Methods 16:293-310. doi: 
10.1006/meth.1998.0686. PMID: 10071068 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
Hibaoui, Y, Grad, I, Letourneau, A, Sailani, MR, Dahoun, S, Santoni, FA, Gimelli, S, Guipponi, M, Pelte, MF, 
Bena, F, Antonarakis, SE and Feki, A (2014) Modelling and rescuing neurodevelopmental defect of 
Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 
21. EMBO Mol Med 6:259-77. doi: 10.1002/emmm.201302848. PMID: 24375627 
Hockemeyer, D, Soldner, F, Beard, C, Gao, Q, Mitalipova, M, DeKelver, RC, Katibah, GE, Amora, R, 
Boydston, EA, Zeitler, B, Meng, X, Miller, JC, Zhang, L, Rebar, EJ, Gregory, PD, Urnov, FD and 
Jaenisch, R (2009) Efficient targeting of expressed and silent genes in human ESCs and iPSCs using 
zinc-finger nucleases. Nat Biotechnol 27:851-7. doi: 10.1038/nbt.1562. PMID: 19680244 
Hockemeyer, D, Wang, H, Kiani, S, Lai, CS, Gao, Q, Cassady, JP, Cost, GJ, Zhang, L, Santiago, Y, Miller, 
JC, Zeitler, B, Cherone, JM, Meng, X, Hinkley, SJ, Rebar, EJ, Gregory, PD, Urnov, FD and Jaenisch, 
R (2011) Genetic engineering of human pluripotent cells using TALE nucleases. Nature Biotechnology 
29:731-734. doi: 10.1038/nbt.1927. PMID: 21738127 
Hollingworth, P, Harold, D, Sims, R, Gerrish, A, Lambert, JC, Carrasquillo, MM, Abraham, R, Hamshere, ML, 
Pahwa, JS, Moskvina, V, Dowzell, K, Jones, N, Stretton, A, Thomas, C, Richards, A, Ivanov, D, 
Widdowson, C, Chapman, J, Lovestone, S, Powell, J, Proitsi, P, Lupton, MK, Brayne, C, Rubinsztein, 
DC, Gill, M, Lawlor, B, Lynch, A, Brown, KS, Passmore, PA, raig, D, McGuinness, B, Todd, S, 
Holmes, C, Mann, D, Smith, AD, Beaumont, H, Warden, D, Wilcock, G, Love, S, Kehoe, PG, Hooper, 
NM, Vardy, ER, Hardy, J, Mead, S, Fox, NC, Rossor, M, Collinge, J, Maier, W, Jessen, F, Ruther, E, 
Schurmann, B, Heun, R, Kolsch, H, van den Bussche, H, Heuser, I, Kornhuber, J, Wiltfang, J, 
Dichgans, M, Frolich, L, Hampel, H, Gallacher, J, Hull, M, Rujescu, D, Giegling, I, Goate, AM, Kauwe, 
JS, Cruchaga, C, Nowotny, P, Morris, JC, Mayo, K, Sleegers, K, Bettens, K, Engelborghs, S, De Deyn, 
PP, Van Broeckhoven, C, Livingston, G, Bass, NJ, Gurling, H, McQuillin, A, Gwilliam, R, Deloukas, P, 
Al-Chalabi, A, Shaw, CE, Tsolaki, M, Singleton, AB, Guerreiro, R, Muhleisen, TW, Nothen, MM, 
Moebus, S, Jockel, KH, Klopp, N, Wichmann, HE, Pankratz, VS, Sando, SB, Aasly, JO, Barcikowska, 
M, Wszolek, ZK, Dickson, DW, Graff-Radford, NR, Petersen, RC, Alzheimer's Disease Neuroimaging, 
I, van Duijn, CM, Breteler, MM, Ikram, MA, DeStefano, AL, Fitzpatrick, AL, Lopez, O, Launer, LJ, 
Seshadri, S, consortium, C, Berr, C, Campion, D, Epelbaum, J, Dartigues, JF, Tzourio, C, Alperovitch, 
A, Lathrop, M, consortium, E, Feulner, TM, Friedrich, P, Riehle, C, Krawczak, M, Schreiber, S, 
Mayhaus, M, Nicolhaus, S, Wagenpfeil, S, Steinberg, S, Stefansson, H, Stefansson, K, Snaedal, J, 
Bjornsson, S, Jonsson, PV, Chouraki, V, Genier-Boley, B, Hiltunen, M, Soininen, H, Combarros, O, 
Zelenika, D, Delepine, M, Bullido, MJ, Pasquier, F, Mateo, I, Frank-Garcia, A, Porcellini, E, Hanon, O, 
Coto, E, Alvarez, V, Bosco, P, Siciliano, G, Mancuso, M, Panza, F, Solfrizzi, V, Nacmias, B, Sorbi, S, 
Bossu, P, Piccardi, P, Arosio, B, Annoni, G, Seripa, D, Pilotto, A, Scarpini, E, Galimberti, D, Brice, A, 
Hannequin, D, Licastro, F, Jones, L, Holmans, PA, Jonsson, T, Riemenschneider, M, Morgan, K, 
Younkin, SG, Owen, MJ, O'Donovan, M, Amouyel, P and Williams, J (2011) Common variants at 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat 
Genet 43:429-35. doi: 10.1038/ng.803. PMID: 21460840 
Hossini, AM, Megges, M, Prigione, A, Lichtner, B, Toliat, MR, Wruck, W, Schroter, F, Nuernberg, P, Kroll, H, 
Makrantonaki, E, Zoubouliss, CC and Adjaye, J (2015) Induced pluripotent stem cell-derived neuronal 
cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene 
regulatory networks. BMC Genomics 16:84. doi: 10.1186/s12864-015-1262-5. PMID: 25765079 
Hotta, Y (2008) Ethical issues of the research on human embryonic stem cells. J Int Bioethique 19:77-85, 
124-5. PMID: 19244943 
Hsu, PD, Lander, ES and Zhang, F (2014) Development and applications of CRISPR-Cas9 for genome 
engineering. Cell 157:1262-78. doi: 10.1016/j.cell.2014.05.010. PMID: 24906146 
Hsu, PD, Scott, DA, Weinstein, JA, Ran, FA, Konermann, S, Agarwala, V, Li, Y, Fine, EJ, Wu, X, Shalem, O, 
Cradick, TJ, Marraffini, LA, Bao, G and Zhang, F (2013) DNA targeting specificity of RNA-guided Cas9 
nucleases. Nat Biotechnol 31:827-32. doi: 10.1038/nbt.2647. PMID: 23873081 
Hu, B-Y, Weick, JP, Yu, J, Ma, L-X, Zhang, X-Q, Thomson, JA and Zhang, S-C (2010) Neural differentiation 
of human induced pluripotent stem cells follows developmental principles but with variable potency. 
Proceedings of the National Academy of Sciences 107:4335-4340. doi: 10.1073/pnas.0910012107.  
Hu, BY, Du, ZW and Zhang, SC (2009) Differentiation of human oligodendrocytes from pluripotent stem cells. 
Nat Protoc 4:1614-22. doi: 10.1038/nprot.2009.186. PMID: 19834476 
Hutton, M, Lendon, CL, Rizzu, P, Baker, M, Froelich, S, Houlden, HH, Pickering-Brown, S, Chakraverty, S, 
Isaacs, A, Grover, A, Hackett, J, Adamson, J, Lincoln, S, Dickson, D, Davies, P, Petersen, RC, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
Stevena, M, De Graaff, E, Wauters, E, Van Baren, J, Hillebrand, M, Joosse, M, Kwon, JM, Nowotny, 
P, Che, LK, Norton, J, Morris, JC, Reed, LA, Trojanowski, J, Basun, H, Lannfelt, L, Neystat, M, Fahn, 
S, Dark, F, Tannenberg, T, Dodd, PR, Hayward, N, Kwok, JBJ, Schofield, PR, Andreadis, A, Snowden, 
J, Craufurd, D, Neary, D, Owen, F, Costra, BA, Hardy, J, Goate, A, Van Swieten, J, Mann, D, Lynch, T 
and Heutink, P (1998) Association of missense and 5'-splice-site mutations in tau with the inherited 
dementia FTDP-17. Nature 393:702-704. PMID: 9641683 
Iovino, M, Agathou, S, Gonzalez-Rueda, A, Del Castillo Velasco-Herrera, M, Borroni, B, Alberici, A, Lynch, T, 
O'Dowd, S, Geti, I, Gaffney, D, Vallier, L, Paulsen, O, Karadottir, RT and Spillantini, MG (2015) Early 
maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients 
with MAPT mutations. Brain. doi: 10.1093/brain/awv222. PMID: 26220942 
Isobe, K, Cheng, Z, Nishio, N, Suganya, T, Tanaka, Y and Ito, S (2014) iPSCs, aging and age-related 
diseases. N Biotechnol 31:411-21. doi: 10.1016/j.nbt.2014.04.004. PMID: 24784583 
Israel, MA, Yuan, SH, Bardy, C, Reyna, SM, Mu, Y, Herrera, C, Hefferan, MP, Van Gorp, S, Nazor, KL, 
Boscolo, FS, Carson, CT, Laurent, LC, Marsala, M, Gage, FH, Remes, AM, Koo, EH and Goldstein, 
LS (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. 
Nature 482:216-20. doi: 10.1038/nature10821. PMID: 22278060 
Jang, J, Kang, HC, Kim, HS, Kim, JY, Huh, YJ, Kim, DS, Yoo, JE, Lee, JA, Lim, B, Lee, J, Yoon, TM, Park, 
IH, Hwang, DY, Daley, GQ and Kim, DW (2011) Induced pluripotent stem cell models from X-linked 
adrenoleukodystrophy patients. Ann Neurol 70:402-9. doi: 10.1002/ana.22486. PMID: 21721033 
Jarrett, JT, Berger, EP and Lansbury, PT, Jr. (1993) The carboxy terminus of the beta amyloid protein is 
critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. 
Biochemistry 32:4693-7. PMID: 8490014 
Jessen, NA, Munk, AS, Lundgaard, I and Nedergaard, M (2015) The Glymphatic System: A Beginner's Guide. 
Neurochem Res. doi: 10.1007/s11064-015-1581-6. PMID: 25947369 
Jinek, M, Chylinski, K, Fonfara, I, Hauer, M, Doudna, JA and Charpentier, E (2012) A programmable dual-
RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816-821.  
Jonsson, T, Stefansson, H, Steinberg, S, Jonsdottir, I, Jonsson, PV, Snaedal, J, Bjornsson, S, Huttenlocher, 
J, Levey, AI, Lah, JJ, Rujescu, D, Hampel, H, Giegling, I, Andreassen, OA, Engedal, K, Ulstein, I, 
Djurovic, S, Ibrahim-Verbaas, C, Hofman, A, Ikram, MA, van Duijn, CM, Thorsteinsdottir, U, Kong, A 
and Stefansson, K (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J 
Med 368:107-16. doi: 10.1056/NEJMoa1211103. PMID: 23150908 
Joung, JK and Sander, JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat 
Rev Mol Cell Biol 14:49-55. doi: 10.1038/nrm3486. PMID: 23169466 
Kadoshima, T, Sakaguchi, H, Nakano, T, Soen, M, Ando, S, Eiraku, M and Sasai, Y (2013) Self-organization 
of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-
derived neocortex. Proc Natl Acad Sci U S A 110:20284-9. doi: 10.1073/pnas.1315710110. PMID: 
24277810 
Kamm, FM (2005) Ethical issues in using and not using embryonic stem cells. Stem Cell Rev 1:325-30. doi: 
10.1385/SCR:1:4:325. PMID: 17142875 
Kanekiyo, T, Xu, H and Bu, G (2014) ApoE and Abeta in Alzheimer's disease: accidental encounters or 
partners? Neuron 81:740-54. doi: 10.1016/j.neuron.2014.01.045. PMID: 24559670 
Kang, J, Lemaire, HG, Unterbeck, A, Salbaum, JM, Masters, CL, Grzeschik, KH, Multhaup, G, Beyreuther, K 
and Muller-Hill, B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-
surface receptor. Nature 325:733-6. doi: 10.1038/325733a0. PMID: 2881207 
Khakh, BS and McCarthy, KD (2015) Astrocyte calcium signaling: from observations to functions and the 
challenges therein. Cold Spring Harb Perspect Biol 7:a020404. doi: 10.1101/cshperspect.a020404. 
PMID: 25605709 
Khurana, V, Tardiff, DF, Chung, CY and Lindquist, S (2015) Toward stem cell-based phenotypic screens for 
neurodegenerative diseases. Nat Rev Neurol 11:339-350. doi: 10.1038/nrneurol.2015.79. PMID: 
25986505 
Kim, D, Frank, CL, Dobbin, MM, Tsunemoto, RK, Tu, W, Peng, PL, Guan, JS, Lee, BH, Moy, LY, Giusti, P, 
Broodie, N, Mazitschek, R, Delalle, I, Haggarty, SJ, Neve, RL, Lu, Y and Tsai, LH (2008) Deregulation 
of HDAC1 by p25/Cdk5 in Neurotoxicity. Neuron 60:803-817. PMID: 19081376 
Kim, DS, Lee, DR, Kim, HS, Yoo, JE, Jung, SJ, Lim, BY, Jang, J, Kang, HC, You, S, Hwang, DY, Leem, JW, 
Nam, TS, Cho, SR and Kim, DW (2012) Highly pure and expandable PSA-NCAM-positive neural 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
precursors from human ESC and iPSC-derived neural rosettes. PLoS One 7:e39715. doi: 
10.1371/journal.pone.0039715. PMID: 22911689 
Kim, H, Lee, G, Ganat, Y, Papapetrou, EP, Lipchina, I, Socci, ND, Sadelain, M and Studer, L (2011) miR-371-
3 Expression Predicts Neural Differentiation Propensity in Human Pluripotent Stem Cells. Cell Stem 
Cell 8:695-706. doi: 10.1016/j.stem.2011.04.002. PMID: 21624813 
Kim, J, Basak, JM and Holtzman, DM (2009) The Role of Apolipoprotein E in Alzheimer's Disease. Neuron 
63:287-303. PMID: 19679070 
Kim, K, Doi, A, Wen, B, Ng, K, Zhao, R, Cahan, P, Kim, J, Aryee, MJ, Ji, H, Ehrlich, LIR, Yabuuchi, A, 
Takeuchi, A, Cunniff, KC, Hongguang, H, McKinney-Freeman, S, Naveiras, O, Yoon, TJ, Irizarry, RA, 
Jung, N, Seita, J, Hanna, J, Murakami, P, Jaenisch, R, Weissleder, R, Orkin, SH, Weissman, IL, 
Feinberg, AP and Daley, GQ (2010) Epigenetic memory in induced pluripotent stem cells. Nature 
467:285-U60. doi: 10.1038/nature09342. PMID: 20644535 
Kim, YH, Choi, SH, D'Avanzo, C, Hebisch, M, Sliwinski, C, Bylykbashi, E, Washicosky, KJ, Klee, JB, Brustle, 
O, Tanzi, RE and Kim, DY (2015) A 3D human neural cell culture system for modeling Alzheimer's 
disease. Nat Protoc 10:985-1006. doi: 10.1038/nprot.2015.065. PMID: 26068894 
King, NM and Perrin, J (2014) Ethical issues in stem cell research and therapy. Stem Cell Res Ther 5:85. doi: 
10.1186/scrt474. PMID: 25157428 
Kobayashi, K, Hayashi, M, Nakano, H, Fukutani, Y, Sasaki, K, Shimazaki, M and Koshino, Y (2002) Apoptosis 
of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in 
Alzheimer's disease. Neuropathol Appl Neurobiol 28:238-51. PMID: 12060348 
Koch, P, Tamboli, IY, Mertens, J, Wunderlich, P, Ladewig, J, Stuber, K, Esselmann, H, Wiltfang, J, Brustle, O 
and Walter, J (2012) Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit 
partial loss of gamma-secretase activity in endogenous amyloid-beta generation. Am J Pathol 
180:2404-16. doi: 10.1016/j.ajpath.2012.02.012. PMID: 22510327 
Koche, RP, Smith, ZD, Adli, M, Gu, HC, Ku, MC, Gnirke, A, Bernstein, BE and Meissner, A (2011) 
Reprogramming Factor Expression Initiates Widespread Targeted Chromatin Remodeling. Cell Stem 
Cell 8:96-105. doi: 10.1016/j.stem.2010.12.001. PMID: 21211784 
Kondo, T, Asai, M, Tsukita, K, Kutoku, Y, Ohsawa, Y, Sunada, Y, Imamura, K, Egawa, N, Yahata, N, Okita, K, 
Takahashi, K, Asaka, I, Aoi, T, Watanabe, A, Watanabe, K, Kadoya, C, Nakano, R, Watanabe, D, 
Maruyama, K, Hori, O, Hibino, S, Choshi, T, Nakahata, T, Hioki, H, Kaneko, T, Naitoh, M, Yoshikawa, 
K, Yamawaki, S, Suzuki, S, Hata, R, Ueno, S, Seki, T, Kobayashi, K, Toda, T, Murakami, K, Irie, K, 
Klein, WL, Mori, H, Asada, T, Takahashi, R, Iwata, N, Yamanaka, S and Inoue, H (2013) Modeling 
Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and 
differential drug responsiveness. Cell Stem Cell 12:487-96. doi: 10.1016/j.stem.2013.01.009. PMID: 
23434393 
Kosik, KS, Joachim, CL and Selkoe, DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic 
component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83:4044-8. 
PMID: 2424016 
Kraepelin, E (1910) Psychiatrie. Barth, Leipzig. 
Krantic, S, Isorce, N, Mechawar, N, Davoli, MA, Vignault, E, Albuquerque, M, Chabot, JG, Moyse, E, Chauvin, 
JP, Aubert, I, McLaurin, J and Quirion, R (2012) Hippocampal GABAergic neurons are susceptible to 
amyloid-beta toxicity in vitro and are decreased in number in the Alzheimer's disease TgCRND8 
mouse model. J Alzheimers Dis 29:293-308. doi: 10.3233/JAD-2011-110830. PMID: 22232004 
Krencik, R, Weick, JP, Liu, Y, Zhang, ZJ and Zhang, SC (2011) Specification of transplantable astroglial 
subtypes from human pluripotent stem cells. Nat Biotechnol 29:528-34. doi: 10.1038/nbt.1877. PMID: 
21602806 
Krencik, R and Zhang, SC (2011) Directed differentiation of functional astroglial subtypes from human 
pluripotent stem cells. Nat Protoc 6:1710-7. doi: 10.1038/nprot.2011.405. PMID: 22011653 
Lai, S, Zhang, M, Xu, D, Zhang, Y, Qiu, L, Tian, C and Zheng, JC (2015) Direct reprogramming of induced 
neural progenitors: a new promising strategy for AD treatment. Transl Neurodegener 4:7. doi: 
10.1186/s40035-015-0028-y. PMID: 25949812 
Lambert, JC, Heath, S, Even, G, Campion, D, Sleegers, K, Hiltunen, M, Combarros, O, Zelenika, D, Bullido, 
MJ, Tavernier, B, Letenneur, L, Bettens, K, Berr, C, Pasquier, F, Fievet, N, Barberger-Gateau, P, 
Engelborghs, S, De Deyn, P, Mateo, I, Franck, A, Helisalmi, S, Porcellini, E, Hanon, O, European 
Alzheimer's Disease Initiative, I, de Pancorbo, MM, Lendon, C, Dufouil, C, Jaillard, C, Leveillard, T, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
24 
Alvarez, V, Bosco, P, Mancuso, M, Panza, F, Nacmias, B, Bossu, P, Piccardi, P, Annoni, G, Seripa, D, 
Galimberti, D, Hannequin, D, Licastro, F, Soininen, H, Ritchie, K, Blanche, H, Dartigues, JF, Tzourio, 
C, Gut, I, Van Broeckhoven, C, Alperovitch, A, Lathrop, M and Amouyel, P (2009) Genome-wide 
association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 
41:1094-9. doi: 10.1038/ng.439. PMID: 19734903 
Lambert, JC, Ibrahim-Verbaas, CA, Harold, D, Naj, AC, Sims, R, Bellenguez, C, Jun, G, Destefano, AL, Bis, 
JC, Beecham, GW, Grenier-Boley, B, Russo, G, Thornton-Wells, TA, Jones, N, Smith, AV, Chouraki, 
V, Thomas, C, Ikram, MA, Zelenika, D, Vardarajan, BN, Kamatani, Y, Lin, CF, Gerrish, A, Schmidt, H, 
Kunkle, B, Dunstan, ML, Ruiz, A, Bihoreau, MT, Choi, SH, Reitz, C, Pasquier, F, Hollingworth, P, 
Ramirez, A, Hanon, O, Fitzpatrick, AL, Buxbaum, JD, Campion, D, Crane, PK, Baldwin, C, Becker, T, 
Gudnason, V, Cruchaga, C, Craig, D, Amin, N, Berr, C, Lopez, OL, De Jager, PL, Deramecourt, V, 
Johnston, JA, Evans, D, Lovestone, S, Letenneur, L, Moron, FJ, Rubinsztein, DC, Eiriksdottir, G, 
Sleegers, K, Goate, AM, Fievet, N, Huentelman, MJ, Gill, M, Brown, K, Kamboh, MI, Keller, L, 
Barberger-Gateau, P, McGuinness, B, Larson, EB, Green, R, Myers, AJ, Dufouil, C, Todd, S, Wallon, 
D, Love, S, Rogaeva, E, Gallacher, J, St George-Hyslop, P, Clarimon, J, Lleo, A, Bayer, A, Tsuang, 
DW, Yu, L, Tsolaki, M, Bossu, P, Spalletta, G, Proitsi, P, Collinge, J, Sorbi, S, Sanchez-Garcia, F, Fox, 
NC, Hardy, J, Naranjo, MC, Bosco, P, Clarke, R, Brayne, C, Galimberti, D, Mancuso, M, Matthews, F, 
European Alzheimer's Disease, I, Genetic, Environmental Risk in Alzheimer's, D, Alzheimer's Disease 
Genetic, C, Cohorts for, H, Aging Research in Genomic, E, Moebus, S, Mecocci, P, Del Zompo, M, 
Maier, W, Hampel, H, Pilotto, A, Bullido, M, Panza, F, Caffarra, P, Nacmias, B, Gilbert, JR, Mayhaus, 
M, Lannfelt, L, Hakonarson, H, Pichler, S, Carrasquillo, MM, Ingelsson, M, Beekly, D, Alvarez, V, Zou, 
F, Valladares, O, Younkin, SG, Coto, E, Hamilton-Nelson, KL, Gu, W, Razquin, C, Pastor, P, Mateo, I, 
Owen, MJ, Faber, KM, Jonsson, PV, Combarros, O, O'Donovan, MC, Cantwell, LB, Soininen, H, 
Blacker, D, Mead, S, Mosley, TH, Jr., Bennett, DA, Harris, TB, Fratiglioni, L, Holmes, C, de Bruijn, RF, 
Passmore, P, Montine, TJ, Bettens, K, Rotter, JI, Brice, A, Morgan, K, Foroud, TM, Kukull, WA, 
Hannequin, D, Powell, JF, Nalls, MA, Ritchie, K, Lunetta, KL, Kauwe, JS, Boerwinkle, E, 
Riemenschneider, M, Boada, M, Hiltunen, M, Martin, ER, Schmidt, R, Rujescu, D, Wang, LS, 
Dartigues, JF, Mayeux, R, Tzourio, C, Hofman, A, Nothen, MM, Graff, C, Psaty, BM, Jones, L, Haines, 
JL, Holmans, PA, Lathrop, M, Pericak-Vance, MA, Launer, LJ, Farrer, LA, van Duijn, CM, Van 
Broeckhoven, C, Moskvina, V, Seshadri, S, Williams, J, Schellenberg, GD and Amouyel, P (2013) 
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat 
Genet. doi: 10.1038/ng.2802. PMID: 24162737 
Lambert, JC, Grenier-Boley, B, Chouraki, V, Heath, S, Zelenika, D, Fievet, N, Hannequin, D, Pasquier, F, 
Hanon, O, Brice, A, Epelbaum, J, Berr, C, Dartigues, JF, Tzourio, C, Campion, D, Lathrop, M and 
Amouyel, P (2010) Implication of the immune system in Alzheimer's disease: evidence from genome-
wide pathway analysis. J Alzheimers Dis 20:1107-18. doi: 10.3233/JAD-2010-100018. PMID: 
20413860 
Lancaster, MA, Renner, M, Martin, C-A, Wenzel, D, Bicknell, LS, Hurles, ME, Homfray, T, Penninger, JM, 
Jackson, AP and Knoblich, JA (2013) Cerebral organoids model human brain development and 
microcephaly. Nature 501:373-+. doi: 10.1038/nature12517. PMID: 23995685 
Lancaster, MA and Knoblich, JA (2014) Generation of cerebral organoids from human pluripotent stem cells. 
Nat Protoc 9:2329-40. doi: 10.1038/nprot.2014.158. PMID: 25188634 
Lassmann, H, Bancher, C, Breitschopf, H, Wegiel, J, Bobinski, M, Jellinger, K and Wisniewski, HM (1995) 
Cell-Death in Alzheimers-Disease Evaluated by DNA Fragmentation in-Situ. Acta Neuropathologica 
89:35-41. PMID: 7709729 
Lee, G, Papapetrou, EP, Kim, H, Chambers, SM, Tomishima, MJ, Fasano, CA, Ganat, YM, Menon, J, 
Shimizu, F, Viale, A, Tabar, V, Sadelain, M and Studer, L (2009) Modelling pathogenesis and 
treatment of familial dysautonomia using patient-specific iPSCs. Nature 461:402-406. PMID: 
19693009 
Lee, MS, Kao, SC, Lemere, CA, Xia, W, Tseng, HC, Zhou, Y, Neve, R, Ahlijanian, MK and Tsai, LH (2003) 
APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163:83-95. doi: 
10.1083/jcb.200301115 
jcb.200301115 [pii]. PMID: 14557249 
Lemere, CA, Blusztajn, JK, Yamaguchi, H, Wisniewski, T, Saido, TC and Selkoe, DJ (1996) Sequence of 
deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
initial events in amyloid plaque formation. Neurobiol Dis 3:16-32. doi: 10.1006/nbdi.1996.0003. PMID: 
9173910 
Levy-Lahad, E, Wijsman, EM, Nemens, E, Anderson, L, Goddard, KA, Weber, JL, Bird, TD and Schellenberg, 
GD (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269:970-3. PMID: 
7638621 
Levy-Lahad, E, Wasco, W, Poorkaj, P, Romano, DM, Oshima, J, Pettingell, WH, Yu, CE, Jondro, PD, 
Schmidt, SD, Wang, K and et al. (1995) Candidate gene for the chromosome 1 familial Alzheimer's 
disease locus. Science 269:973-7. PMID: 7638622 
Li, S, Mallory, M, Alford, M, Tanaka, S and Masliah, E (1997) Glutamate transporter alterations in Alzheimer 
disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56:901-11. 
PMID: 9258260 
Lippmann, ES, Al-Ahmad, A, Azarin, SM, Palecek, SP and Shusta, EV (2014) A retinoic acid-enhanced, 
multicellular human blood-brain barrier model derived from stem cell sources. Sci Rep 4:4160. doi: 
10.1038/srep04160. PMID: 24561821 
Lippmann, ES, Al-Ahmad, A, Palecek, SP and Shusta, EV (2013) Modeling the blood-brain barrier using stem 
cell sources. Fluids Barriers CNS 10:2. doi: 10.1186/2045-8118-10-2. PMID: 23305164 
Lippmann, ES, Azarin, SM, Kay, JE, Nessler, RA, Wilson, HK, Al-Ahmad, A, Palecek, SP and Shusta, EV 
(2012) Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. Nature 
Biotechnology 30:783-791. doi: 10.1038/nbt.2247. PMID: 22729031 
Lister, R, Pelizzola, M, Kida, YS, Hawkins, RD, Nery, JR, Hon, G, Antosiewicz-Bourget, J, O'Malley, R, 
Castanon, R, Klugman, S, Downes, M, Yu, R, Stewart, R, Ren, B, Thomson, JA, Evans, RM and 
Ecker, JR (2011) Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem 
cells. Nature 471:68-U84. doi: 10.1038/nature09798. PMID: 21289626 
Liu, CC, Kanekiyo, T, Xu, H and Bu, G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and 
therapy. Nature Reviews Neurology. PMID: 23296339 
Liu, GH, Barkho, BZ, Ruiz, S, Diep, D, Qu, J, Yang, SL, Panopoulos, AD, Suzuki, K, Kurian, L, Walsh, C, 
Thompson, J, Boue, S, Fung, HL, Sancho-Martinez, I, Zhang, K, Yates, J, 3rd and Izpisua Belmonte, 
JC (2011) Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. 
Nature 472:221-5. doi: 10.1038/nature09879. PMID: 21346760 
Liu, GH, Qu, J, Suzuki, K, Nivet, E, Li, M, Montserrat, N, Yi, F, Xu, X, Ruiz, S, Zhang, W, Wagner, U, Kim, A, 
Ren, B, Li, Y, Goebl, A, Kim, J, Soligalla, RD, Dubova, I, Thompson, J, Yates, J, 3rd, Esteban, CR, 
Sancho-Martinez, I and Izpisua Belmonte, JC (2012) Progressive degeneration of human neural stem 
cells caused by pathogenic LRRK2. Nature 491:603-7. doi: 10.1038/nature11557. PMID: 23075850 
Liu, H and Zhang, SC (2011) Specification of neuronal and glial subtypes from human pluripotent stem cells. 
Cell Mol Life Sci 68:3995-4008. doi: 10.1007/s00018-011-0770-y. PMID: 21786144 
Liu, Y, Liu, H, Sauvey, C, Yao, L, Zarnowska, ED and Zhang, SC (2013) Directed differentiation of forebrain 
GABA interneurons from human pluripotent stem cells. Nat Protoc 8:1670-9. doi: 
10.1038/nprot.2013.106. PMID: 23928500 
Lomax, GP, Hull, SC and Isasi, R (2015) The DISCUSS Project: Revised Points to Consider for the Derivation 
of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens. Stem Cells 
Transl Med 4:123-9. doi: 10.5966/sctm.2014-0192. PMID: 25561681 
Lomax, GP and Peckman, SR (2012) Stem cell policy exceptionalism: proceed with caution. Stem Cell Rev 
8:299-304. doi: 10.1007/s12015-011-9305-z. PMID: 21837381 
Lomax, GP, Hull, SC, Lowenthal, J, Rao, M and Isasi, R (2013) The DISCUSS Project: induced pluripotent 
stem cell lines from previously collected research biospecimens and informed consent: points to 
consider. Stem Cells Transl Med 2:727-30. doi: 10.5966/sctm.2013-0099. PMID: 23990574 
Lovell, MA and Markesbery, WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage 
Alzheimer's disease. Nucleic Acids Research 35:7497-7504.  
Lu, T, Pan, Y, Kao, SY, Li, C, Kohane, I, Chan, J and Yankner, BA (2004) Gene regulation and DNA damage 
in the ageing human brain. Nature 429:883-891.  
Lue, LF, Walker, DG and Rogers, J (2001) Modeling microglial activation in Alzheimer's disease with human 
postmortem microglial cultures. Neurobiology of Aging 22:945-956. doi: 10.1016/s0197-
4580(01)00311-6. PMID: 11755003 
Ma, N, Shan, Y, Liao, B, Kong, G, Wang, C, Huang, K, Zhang, H, Cai, X, Chen, S, Pei, D, Chen, N and Pan, 
G (2015) Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
26 
Different Genome Instability in beta-Thalassemia Induced Pluripotent Stem Cells (iPSCs). J Biol Chem 
290:12079-89. doi: 10.1074/jbc.M114.624999. PMID: 25795783 
Ma, YJ, Hill, DF, Creswick, KE, Costa, ME, Cornea, A, Lioubin, MN, Plowman, GD and Ojeda, SR (1999) 
Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine 
control of mammalian sexual development. J Neurosci 19:9913-27. PMID: 10559400 
Maclean, GA, Menne, TF, Guo, G, Sanchez, DJ, Park, IH, Daley, GQ and Orkin, SH (2012) Altered 
hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent 
cells. Proc Natl Acad Sci U S A 109:17567-72. doi: 10.1073/pnas.1215468109. PMID: 23045682 
Mahley, RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 
240. PMID: 3283935 
Mahley, RW and Rall, SC, Jr. (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev 
Genomics Hum Genet. PMID: 11701639 
Mahmoudi, S and Brunet, A (2012) Aging and reprogramming: a two-way street. Curr Opin Cell Biol 24:744-
56. doi: 10.1016/j.ceb.2012.10.004. PMID: 23146768 
Majewski, J and Pastinen, T (2011) The study of eQTL variations by RNA-seq: from SNPs to phenotypes. 
Trends in Genetics 27:72-79. doi: 10.1016/j.tig.2010.10.006. PMID: 21122937 
Major, T, Menon, J, Auyeung, G, Soldner, F, Hockemeyer, D, Jaenisch, R and Tabar, V (2011) Transgene 
excision has no impact on in vivo integration of human iPS derived neural precursors. PLoS One 
6:e24687. doi: 10.1371/journal.pone.0024687. PMID: 21961042 
Mali, P, Yang, L, Esvelt, KM, Aach, J, Guell, M, DiCarlo, JE, Norville, JE and Church, GM (2013) RNA-Guided 
Human Genome Engineering via Cas9. Science (New York, NY). doi: 
papers2://publication/doi/10.1126/science.1232033.  
Mann, EO and Paulsen, O (2007) Role of GABAergic inhibition in hippocampal network oscillations. Trends 
Neurosci 30:343-9. doi: 10.1016/j.tins.2007.05.003. PMID: 17532059 
Marchetto, MCN, Carromeu, C, Acab, A, Yu, D, Yeo, GW, Mu, Y, Chen, G, Gage, FH and Muotri, AR (2010) 
A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent 
Stem Cells. Cell 143:527-539. doi: 10.1016/j.cell.2010.10.016. PMID: 21074045 
Martin, GR (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium 
conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A 78:7634-8. doi: 
10.1073/pnas.78.12.7634. PMID: 6950406 
Masliah, E, Alford, M, Mallory, M, Rockenstein, E, Moechars, D and Van Leuven, F (2000) Abnormal 
Glutamate Transport Function in Mutant Amyloid Precursor Protein Transgenic Mice. Experimental 
Neurology 163:381-387.  
Masumoto, H, Ikuno, T, Takeda, M, Fukushima, H, Marui, A, Katayama, S, Shimizu, T, Ikeda, T, Okano, T, 
Sakata, R and Yamashita, JK (2014) Human iPS cell-engineered cardiac tissue sheets with 
cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep 4:6716. doi: 10.1038/srep06716. 
PMID: 25336194 
Mattis, VB, Tom, C, Akimov, S, Saeedian, J, Ostergaard, ME, Southwell, AL, Doty, CN, Ornelas, L, Sahabian, 
A, Lenaeus, L, Mandefro, B, Sareen, D, Arjomand, J, Hayden, MR, Ross, CA and Svendsen, CN 
(2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF 
withdrawal due to glutamate toxicity. Hum Mol Genet 24:3257-71. doi: 10.1093/hmg/ddv080. PMID: 
25740845 
McBride, R (2012) Pharma counts just 3 Alzheimer's drug wins in 13 years (101 losses!).  FierceBiotech,   
Mertens, J, Stuber, K, Wunderlich, P, Ladewig, J, Kesavan, JC, Vandenberghe, R, Vandenbulcke, M, van 
Damme, P, Walter, J, Brustle, O and Koch, P (2013) APP processing in human pluripotent stem cell-
derived neurons is resistant to NSAID-based gamma-secretase modulation. Stem Cell Reports 1:491-
8. doi: 10.1016/j.stemcr.2013.10.011. PMID: 24371804 
Miller, J and Studer, L (2014) Aging in iPS cells. Aging (Albany NY) 6:246-7. PMID: 24799443 
Miller, JC, Tan, S, Qiao, G, Barlow, KA, Wang, J, Xia, DF, Meng, X, Paschon, DE, Leung, E, Hinkley, SJ, 
Dulay, GP, Hua, KL, Ankoudinova, I, Cost, GJ, Urnov, FD, Zhang, HS, Holmes, MC, Zhang, L, 
Gregory, PD and Rebar, EJ (2011) A TALE nuclease architecture for efficient genome editing. Nat 
Biotechnol 29:143-8. doi: 10.1038/nbt.1755. PMID: 21179091 
Miller, JD, Ganat, YM, Kishinevsky, S, Bowman, RL, Liu, B, Tu, EY, Mandal, PK, Vera, E, Shim, JW, Kriks, S, 
Taldone, T, Fusaki, N, Tomishima, MJ, Krainc, D, Milner, TA, Rossi, DJ and Studer, L (2013) Human 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
27 
iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13:691-705. 
doi: 10.1016/j.stem.2013.11.006. PMID: 24315443 
Minami, H, Tashiro, K, Okada, A, Hirata, N, Yamaguchi, T, Takayama, K, Mizuguchi, H and Kawabata, K 
(2015) Generation of Brain Microvascular Endothelial-Like Cells from Human Induced Pluripotent 
Stem Cells by Co-Culture with C6 Glioma Cells. PLoS One 10:e0128890. doi: 
10.1371/journal.pone.0128890. PMID: 26061227 
Monoranu, CM, Apfelbacher, M, Gruenblatt, E, Puppe, B, Alafuzoff, I, Ferrer, I, Al-Saraj, S, Keyvani, K, 
Schmitt, A, Falkai, P, Schittenhelm, J, Halliday, G, Kril, J, Harper, C, McLean, C, Riederer, P and 
Roggendorf, W (2009) Abstracts of the 110th Meeting of the British Neuropathological Society. 
January 7-9, 2009. London, United Kingdom. Neuropathol Appl Neurobiol 35 Suppl 1:1-38. doi: 
10.1111/j.1365-2990.2008.01003.x. PMID: 19146648 
Muratore, CR, Rice, HC, Srikanth, P, Callahan, DG, Shin, T, Benjamin, LN, Walsh, DM, Selkoe, DJ and 
Young-Pearse, TL (2014) The familial Alzheimer's disease APPV717I mutation alters APP processing 
and Tau expression in iPSC-derived neurons. Hum Mol Genet 23:3523-36. doi: 10.1093/hmg/ddu064. 
PMID: 24524897 
Murray, A, Letourneau, A, Canzonetta, C, Stathaki, E, Gimelli, S, Sloan-Bena, F, Abrehart, R, Goh, P, Lim, S, 
Baldo, C, Dagna-Bricarelli, F, Hannan, S, Mortensen, M, Ballard, D, Syndercombe Court, D, Fusaki, N, 
Hasegawa, M, Smart, TG, Bishop, C, Antonarakis, SE, Groet, J and Nizetic, D (2015) Brief report: 
isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model 
accelerated neuronal ageing and neurodegeneration. Stem Cells 33:2077-84. doi: 10.1002/stem.1968. 
PMID: 25694335 
Narsinh, KH, Sun, N, Sanchez-Freire, V, Lee, AS, Almeida, P, Hu, S, Jan, T, Wilson, KD, Leong, D, 
Rosenberg, J, Yao, M, Robbins, RC and Wu, JC (2011) Single cell transcriptional profiling reveals 
heterogeneity of human induced pluripotent stem cells. J Clin Invest 121:1217-21. doi: 
10.1172/JCI44635. PMID: 21317531 
Narsinh, KH, Plews, J and Wu, JC (2011) Comparison of human induced pluripotent and embryonic stem 
cells: fraternal or identical twins? Mol Ther 19:635-8. doi: 10.1038/mt.2011.41. PMID: 21455209 
Nazor, KL, Altun, G, Lynch, C, Tran, H, Harness, JV, Slavin, I, Garitaonandia, I, Muller, FJ, Wang, YC, 
Boscolo, FS, Fakunle, E, Dumevska, B, Lee, S, Park, HS, Olee, T, D'Lima, DD, Semechkin, R, Parast, 
MM, Galat, V, Laslett, AL, Schmidt, U, Keirstead, HS, Loring, JF and Laurent, LC (2012) Recurrent 
variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. Cell 
Stem Cell 10:620-34. doi: 10.1016/j.stem.2012.02.013. PMID: 22560082 
Neumann, HJ-B-S, 53123 Bonn, DE), Roy, Kristin (Karl-Barth-Str. 69, 53129 Bonn, DE), Brüstle, Oliver  (c/o 
Institut für RekonstruktiveNeurobiologieUniversität BonnSigmund-Freud-Str. 25, 53127 Bonn, DE), 
Peitz, Michael (Aloys-Schulte-Str. 28, 53129 Bonn, DE), (2012) Method for obtaining human microglial 
precursor cells from pluripotent stem cells.  Life & Brain GmbH (Sigmund-Freud-Straße 25, 53127 
Bonn, DE),Rheinische, Friedrich-wilhelms-universität (Regina-Pacis-Weg 3, 53113 Bonn, DE),,   
Nieweg, K, Andreyeva, A, van Stegen, B, Tanriover, G and Gottmann, K (2015) Alzheimer's disease-related 
amyloid-beta induces synaptotoxicity in human iPS cell-derived neurons. Cell Death Dis 6:e1709. doi: 
10.1038/cddis.2015.72. PMID: 25837485 
Oberheim, NA, Wang, X, Goldman, S and Nedergaard, M (2006) Astrocytic complexity distinguishes the 
human brain. Trends Neurosci 29:547-53. doi: 10.1016/j.tins.2006.08.004. PMID: 16938356 
Oberheim, NA, Takano, T, Han, X, He, W, Lin, JHC, Wang, F, Xu, Q, Wyatt, JD, Pilcher, W, Ojemann, JG, 
Ransom, BR, Goldman, SA and Nedergaard, M (2009) Uniquely Hominid Features of Adult Human 
Astrocytes. J. Neurosci. 29:3276-3287. doi: 10.1523/jneurosci.4707-08.2009.  
Odawara, A, Saitoh, Y, Alhebshi, AH, Gotoh, M and Suzuki, I (2014) Long-term electrophysiological activity 
and pharmacological response of a human induced pluripotent stem cell-derived neuron and astrocyte 
co-culture. Biochem Biophys Res Commun 443:1176-81. doi: 10.1016/j.bbrc.2013.12.142. PMID: 
24406164 
Ogawa, S, Tokumoto, Y, Miyake, J and Nagamune, T (2011) Induction of oligodendrocyte differentiation from 
adult human fibroblast-derived induced pluripotent stem cells. In Vitro Cell Dev Biol Anim 47:464-9. 
doi: 10.1007/s11626-011-9435-2. PMID: 21695581 
Ohi, Y, Qin, H, Hong, C, Blouin, L, Polo, JM, Guo, T, Qi, Z, Downey, SL, Manos, PD, Rossi, DJ, Yu, J, 
Hebrok, M, Hochedlinger, K, Costello, JF, Song, JS and Ramalho-Santos, M (2011) Incomplete DNA 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 
13:541-9. doi: 10.1038/ncb2239. PMID: 21499256 
Okita, K, Yamakawa, T, Matsumura, Y, Sato, Y, Amano, N, Watanabe, A, Goshima, N and Yamanaka, S 
(2013) An efficient nonviral method to generate integration-free human-induced pluripotent stem cells 
from cord blood and peripheral blood cells. Stem Cells 31:458-66. doi: 10.1002/stem.1293. PMID: 
23193063 
Olgiati, P, Politis, AM, Papadimitriou, GN, De Ronchi, D and Serretti, A (2011) Genetics of late-onset 
Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J 
Alzheimers Dis 2011:832379. doi: 10.4061/2011/832379. PMID: 22191060 
Parent, JM and Anderson, SA (2015) Reprogramming patient-derived cells to study the epilepsies. Nat 
Neurosci 18:360-6. doi: 10.1038/nn.3944. PMID: 25710838 
Park, IH, Arora, N, Huo, H, Maherali, N, Ahfeldt, T, Shimamura, A, Lensch, MW, Cowan, C, Hochedlinger, K 
and Daley, GQ (2008) Disease-specific induced pluripotent stem cells. Cell 134:877-86. doi: S0092-
8674(08)01001-5 [pii] 
10.1016/j.cell.2008.07.041. PMID: 18691744 
Pasca, AM, Sloan, SA, Clarke, LE, Tian, Y, Makinson, CD, Huber, N, Kim, CH, Park, JY, O'Rourke, NA, 
Nguyen, KD, Smith, SJ, Huguenard, JR, Geschwind, DH, Barres, BA and Pasca, SP (2015) Functional 
cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods 12:671-
8. doi: 10.1038/nmeth.3415. PMID: 26005811 
Pascual, O, Casper, KB, Kubera, C, Zhang, J, Revilla-Sanchez, R, Sul, JY, Takano, H, Moss, SJ, McCarthy, 
K and Haydon, PG (2005) Astrocytic purinergic signaling coordinates synaptic networks. Science 
310:113-6. doi: 310/5745/113 [pii] 
10.1126/science.1116916. PMID: 16210541 
Perea, G, Navarrete, M and Araque, A (2009) Tripartite synapses: astrocytes process and control synaptic 
information. Trends in Neurosciences 32:421-431.  
Pfrieger, FW (2009) Roles of glial cells in synapse development. Cell Mol Life Sci 66:2037-47. doi: 
10.1007/s00018-009-0005-7. PMID: 19308323 
Pfrieger, FW and Barres, BA (1997) Synaptic efficacy enhanced by glial cells in vitro. Science 277:1684-7. 
PMID: 9287225 
Portelius, E, Andreasson, U, Ringman, JM, Buerger, K, Daborg, J, Buchhave, P, Hansson, O, Harmsen, A, 
Gustavsson, MK, Hanse, E, Galasko, D, Hampel, H, Blennow, K and Zetterberg, H (2010) Distinct 
cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial 
Alzheimer's disease. Mol Neurodegener 5:2. doi: 10.1186/1750-1326-5-2. PMID: 20145736 
Pouya, A, Satarian, L, Kiani, S, Javan, M and Baharvand, H (2011) Human induced pluripotent stem cells 
differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm 
demyelination. PLoS One 6:e27925. doi: 10.1371/journal.pone.0027925. PMID: 22125639 
Puschmann, TB, Zanden, C, De Pablo, Y, Kirchhoff, F, Pekna, M, Liu, J and Pekny, M (2013) Bioactive 3D 
cell culture system minimizes cellular stress and maintains the in vivo-like morphological complexity of 
astroglial cells. Glia 61:432-40. doi: 10.1002/glia.22446. PMID: 23292921 
Qi, LS, Larson, MH, Gilbert, LA, Doudna, JA, Weissman, JS, Arkin, AP and Lim, WA (2013) Repurposing 
CRISPR as an RNA-γuided platform for sequence-specific control of gene expression. Cell 152:1173-
1183.  
Ran, FA, Hsu, PD, Wright, J, Agarwala, V, Scott, DA and Zhang, F (2013) Genome engineering using the 
CRISPR-Cas9 system. Nat Protoc 8:2281-308. doi: 10.1038/nprot.2013.143. PMID: 24157548 
Robakis, NK, Wisniewski, HM, Jenkins, EC, Devine-Gage, EA, Houck, GE, Yao, XL, Ramakrishna, N, Wolfe, 
G, Silverman, WP and Brown, WT (1987) Chromosome 21q21 sublocalisation of gene encoding beta-
amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and 
Down syndrome. Lancet 1:384-5. PMID: 2880184 
Robinson, SR (2001) Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. J 
Neurosci Res 66:972-80. PMID: 11746426 
Rogaev, EI, Sherrington, R, Rogaeva, EA, Levesque, G, Ikeda, M, Llang, Y, Chi, H, Lin, C, Holman, K, Tsuda, 
T, Mar, L, Sorbi, S, Nacmias, B, Piacentini, S, Amaduccl, L, Chumakov, I, Cohen, D, Lannfelt, L and St 
George-Hyslop, PH (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene 
on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
29 
Roth, AD, Ramirez, G, Alarcon, R and Von Bernhardi, R (2005) Oligodendrocytes damage in Alzheimer's 
disease: beta amyloid toxicity and inflammation. Biol Res 38:381-7. PMID: 16579521 
Rouhani, F, Kumasaka, N, de Brito, MC, Bradley, A, Vallier, L and Gaffney, D (2014) Genetic background 
drives transcriptional variation in human induced pluripotent stem cells. PLoS Genet 10:e1004432. doi: 
10.1371/journal.pgen.1004432. PMID: 24901476 
Rumble, B, Retallack, R, Hilbich, C, Simms, G, Multhaup, G, Martins, R, Hockey, A, Montgomery, P, 
Beyreuther, K and Masters, CL (1989) Amyloid A4 protein and its precursor in Down's syndrome and 
Alzheimer's disease. The New England journal of medicine 320:1446-52. doi: papers://3039E21D-
04C9-4FF4-AF76-9D1A38439DE0/Paper/p1254.  
Ryan, SD, Dolatabadi, N, Chan, SF, Zhang, X, Akhtar, MW, Parker, J, Soldner, F, Sunico, CR, Nagar, S, 
Talantova, M, Lee, B, Lopez, K, Nutter, A, Shan, B, Molokanova, E, Zhang, Y, Han, X, Nakamura, T, 
Masliah, E, Yates, JR, 3rd, Nakanishi, N, Andreyev, AY, Okamoto, S, Jaenisch, R, Ambasudhan, R 
and Lipton, SA (2013) Isogenic human iPSC Parkinson's model shows nitrosative stress-induced 
dysfunction in MEF2-PGC1alpha transcription. Cell 155:1351-64. doi: 10.1016/j.cell.2013.11.009. 
PMID: 24290359 
Sahin, E and DePinho, RA (2010) Linking functional decline of telomeres, mitochondria and stem cells during 
ageing. Nature 464:520-528.  
Salloway, S, Sperling, R, Fox, NC, Blennow, K, Klunk, W, Raskind, M, Sabbagh, M, Honig, LS, Porsteinsson, 
AP, Ferris, S, Reichert, M, Ketter, N, Nejadnik, B, Guenzler, V, Miloslavsky, M, Wang, D, Lu, Y, Lull, J, 
Tudor, IC, Liu, E, Grundman, M, Yuen, E, Black, R, Brashear, HR, Bapineuzumab and Clinical Trial, I 
(2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 
370:322-33. doi: 10.1056/NEJMoa1304839. PMID: 24450891 
Samuel, R, Daheron, L, Liao, S, Vardam, T, Kamoun, WS, Batista, A, Buecker, C, Schafer, R, Han, X, Au, P, 
Scadden, DT, Duda, DG, Fukumura, D and Jain, RK (2013) Generation of functionally competent and 
durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S 
A 110:12774-9. doi: 10.1073/pnas.1310675110. PMID: 23861493 
Sander, JD and Joung, JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat 
Biotechnol 32:347-55. doi: 10.1038/nbt.2842. PMID: 24584096 
Sandoe, J and Eggan, K (2013) Opportunities and challenges of pluripotent stem cell neurodegenerative 
disease models. Nat Neurosci 16:780-9. doi: 10.1038/nn.3425. PMID: 23799470 
Schellenberg, GD, Payami, H, Wijsman, EM, Orr, HT, Goddard, KA, Anderson, L, Nemens, E, White, JA, 
Alonso, ME, Ball, MJ and et al. (1993) Chromosome 14 and late-onset familial Alzheimer disease 
(FAD). Am J Hum Genet 53:619-28. PMID: 8352272 
Schwartz, MP, Hou, Z, Propson, NE, Zhang, J, Engstrom, CJ, Costa, VS, Jiang, P, Nguyen, BK, Bolin, JM, 
Daly, W, Wang, Y, Stewart, R, Page, CD, Murphy, WL and Thomson, JA (2015) Human pluripotent 
stem cell-derived neural constructs for predicting neural toxicity. Proc Natl Acad Sci U S A 112:12516-
21. doi: 10.1073/pnas.1516645112. PMID: 26392547 
Selvaraj, V, Jiang, P, Chechneva, O, Lo, UG and Deng, W (2012) Differentiating human stem cells into 
neurons and glial cells for neural repair. Front Biosci (Landmark Ed) 17:65-89. PMID: 22201733 
Sergent-Tanguy, S, Chagneau, C, Neveu, I and Naveilhan, P (2003) Fluorescent activated cell sorting 
(FACS): a rapid and reliable method to estimate the number of neurons in a mixed population. J 
Neurosci Methods 129:73-9. doi: 10.1016/s0165-0270(03)00210-3. PMID: 12951234 
Shalem, O, Sanjana, NE, Hartenian, E, Shi, X, Scott, DA, Mikkelsen, TS, Heckl, D, Ebert, BL, Root, DE, 
Doench, JG and Zhang, F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. 
Science 343:84-7. doi: 10.1126/science.1247005. PMID: 24336571 
Shi, Y, Kirwan, P and Livesey, FJ (2012) Directed differentiation of human pluripotent stem cells to cerebral 
cortex neurons and neural networks. Nat Protoc 7:1836-46. doi: 10.1038/nprot.2012.116. PMID: 
22976355 
Shi, Y, Kirwan, P, Smith, J, Robinson, HP and Livesey, FJ (2012) Human cerebral cortex development from 
pluripotent stem cells to functional excitatory synapses. Nat Neurosci 15:477-86, s1. doi: 
10.1038/nn.3041. PMID: 22306606 
Shi, Y, Kirwan, P, Smith, J, MacLean, G, Orkin, SH and Livesey, FJ (2012) A human stem cell model of early 
Alzheimer's disease pathology in Down syndrome. Sci Transl Med 4:124ra29. doi: 
10.1126/scitranslmed.3003771. PMID: 22344463 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
30 
Shigetomi, E, Bushong, EA, Haustein, MD, Tong, X, Jackson-Weaver, O, Kracun, S, Xu, J, Sofroniew, MV, 
Ellisman, MH and Khakh, BS (2013) Imaging calcium microdomains within entire astrocyte territories 
and endfeet with GCaMPs expressed using adeno-associated viruses. J Gen Physiol 141:633-47. doi: 
10.1085/jgp.201210949. PMID: 23589582 
Shimamoto, A, Yokote, K and Tahara, H (2015) Werner Syndrome-specific induced pluripotent stem cells: 
recovery of telomere function by reprogramming. Front Genet 6:10. doi: 10.3389/fgene.2015.00010. 
PMID: 25688260 
Siegert, S, Cabuy, E, Scherf, BG, Kohler, H, Panda, S, Le, YZ, Fehling, HJ, Gaidatzis, D, Stadler, MB and 
Roska, B (2012) Transcriptional code and disease map for adult retinal cell types. Nat Neurosci 
15:487-95, S1-2. doi: 10.1038/nn.3032. PMID: 22267162 
Smith, AM and Dragunow, M (2014) The human side of microglia. Trends Neurosci 37:125-35. doi: 
10.1016/j.tins.2013.12.001. PMID: 24388427 
Smith, I, Silveirinha, V, Stein, JL, de la Torre-Ubieta, L, Farrimond, JA, Williamson, EM and Whalley, BJ 
(2015) Human neural stem cell-derived cultures in three-dimensional substrates form spontaneously 
functional neuronal networks. J Tissue Eng Regen Med. doi: 10.1002/term.2001. PMID: 25712225 
Soldner, F and Jaenisch, R (2012) iPSC disease modeling. Science 338:1155-1156.  
Soldner, F, Hockemeyer, D, Beard, C, Gao, Q, Bell, GW, Cook, EG, Hargus, G, Blak, A, Cooper, O, 
Mitalipova, M, Isacson, O and Jaenisch, R (2009) Parkinson's disease patient-derived induced 
pluripotent stem cells free of viral reprogramming factors. Cell 136:964-77. doi: S0092-8674(09)00151-
2 [pii] 
10.1016/j.cell.2009.02.013. PMID: 19269371 
Soldner, F, Laganière, J, Cheng, AW, Hockemeyer, D, Gao, Q, Alagappan, R, Khurana, V, Golbe, LI, Myers, 
RH, Lindquist, S, Zhang, L, Guschin, D, Fong, LK, Vu, BJ, Meng, X, Urnov, FD, Rebar, EJ, Gregory, 
PD, Zhang, HS and Jaenisch, R (2011) Generation of Isogenic Pluripotent Stem Cells Differing 
Exclusively at Two Early Onset Parkinson Point Mutations. Cell 146:318-331. doi: 
papers2://publication/doi/10.1016/j.cell.2011.06.019.  
Spillantini, MG, Murrell, JR, Goedert, M, Farlow, MR, Klug, A and Ghetti, B (1998) Mutation in the tau gene in 
familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95:7737-41. 
PMID: 9636220 
Spittaels, K, Van Den Haute, C, Van Dorpe, J, Bruynseels, K, Vandezande, K, Laenen, I, Geerts, H, Mercken, 
M, Sciot, R, Van Lommel, A, Loos, R and Van Leuven, F (1999) Prominent axonopathy in the brain 
and spinal cord of transgenic mice overexpressing four-repeat human tau protein. American Journal 
Of Pathology 155:2153-2165.  
St George-Hyslop, PH, Tanzi, RE, Polinsky, RJ, Haines, JL, Nee, L, Watkins, PC, Myers, RH, Feldman, RG, 
Pollen, D, Drachman, D and et al. (1987) The genetic defect causing familial Alzheimer's disease 
maps on chromosome 21. Science 235:885-90. PMID: 2880399 
Streit, WJ, Braak, H, Xue, QS and Bechmann, I (2009) Dystrophic (senescent) rather than activated microglial 
cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. 
Acta Neuropathol 118:475-85. doi: 10.1007/s00401-009-0556-6. PMID: 19513731 
Streit, WJ and Xue, QS (2010) The Brain's Aging Immune System. Aging Dis 1:254-261. PMID: 21833348 
Sugaya, K, Reeves, M and McKinney, M (1997) Topographic associations between DNA fragmentation and 
Alzheimer's disease neuropathology in the hippocampus. Neurochemistry International 31:275-281. 
doi: Doi 10.1016/S0197-0186(96)00158-1. PMID: 9220460 
Sun, W, McConnell, E, Pare, JF, Xu, Q, Chen, M, Peng, W, Lovatt, D, Han, X, Smith, Y and Nedergaard, M 
(2013) Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. 
Science 339:197-200. doi: 10.1126/science.1226740. PMID: 23307741 
Swistowski, A, Peng, J, Liu, Q, Mali, P, Rao, MS, Cheng, L and Zeng, X (2010) Efficient generation of 
functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. 
Stem Cells 28:1893-904. doi: 10.1002/stem.499. PMID: 20715183 
Tabata, H (2015) Diverse subtypes of astrocytes and their development during corticogenesis. Front Neurosci 
9:114. doi: 10.3389/fnins.2015.00114. PMID: 25904839 
Tada, M, Takahama, Y, Abe, K, Nakatsuji, N and Tada, T (2001) Nuclear reprogramming of somatic cells by 
in vitro hybridization with ES cells. Curr Biol 11:1553-8. doi: 10.1016/s0960-9822(01)00459-6. PMID: 
11591326 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
Takahashi, K, Tanabe, K, Ohnuki, M, Narita, M, Ichisaka, T, Tomoda, K and Yamanaka, S (2007) Induction of 
pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-72. doi: S0092-
8674(07)01471-7 [pii] 
10.1016/j.cell.2007.11.019. PMID: 18035408 
Takahashi, K and Yamanaka, S (2006) Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult 
Fibroblast Cultures by Defined Factors. Cell 126:663-676.  
Takebe, T, Sekine, K, Enomura, M, Koike, H, Kimura, M, Ogaeri, T, Zhang, RR, Ueno, Y, Zheng, YW, Koike, 
N, Aoyama, S, Adachi, Y and Taniguchi, H (2013) Vascularized and functional human liver from an 
iPSC-derived organ bud transplant. Nature 499:481-4. doi: 10.1038/nature12271. PMID: 23823721 
Tanzi, RE, Gusella, JF, Watkins, PC, Bruns, GA, St George-Hyslop, P, Van Keuren, ML, Patterson, D, Pagan, 
S, Kurnit, DM and Neve, RL (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic 
linkage near the Alzheimer locus. Science 235:880-4. PMID: 2949367 
Telias, M and Ben-Yosef, D (2014) Modeling neurodevelopmental disorders using human pluripotent stem 
cells. Stem Cell Rev 10:494-511. doi: 10.1007/s12015-014-9507-2. PMID: 24728983 
Thomson, JA, Itskovitz-Eldor, J, Shapiro, SS, Waknitz, MA, Swiergiel, JJ, Marshall, VS and Jones, JM (1998) 
Embryonic stem cell lines derived from human blastocysts. Science 282:1145-7. PMID: 9804556 
Tilleux, S and Hermans, E (2007) Neuroinflammation and regulation of glial glutamate uptake in neurological 
disorders. J Neurosci Res 85:2059-70. doi: 10.1002/jnr.21325. PMID: 17497670 
Tonnesen, J, Katona, G, Rozsa, B and Nagerl, UV (2014) Spine neck plasticity regulates 
compartmentalization of synapses. Nat Neurosci 17:678-85. doi: 10.1038/nn.3682. PMID: 24657968 
Tsai, SQ, Zheng, Z, Nguyen, NT, Liebers, M, Topkar, VV, Thapar, V, Wyvekens, N, Khayter, C, Iafrate, AJ, 
Le, LP, Aryee, MJ and Joung, JK (2015) GUIDE-seq enables genome-wide profiling of off-target 
cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187-97. doi: 10.1038/nbt.3117. PMID: 
25513782 
Tsuchiya, T, Park, KC, Toyonaga, S, Yamada, SM, Nakabayashi, H, Nakai, E, Ikawa, N, Furuya, M, 
Tominaga, A and Shimizu, K (2005) Characterization of microglia induced from mouse embryonic 
stem cells and their migration into the brain parenchyma. J Neuroimmunol 160:210-8. doi: 
10.1016/j.jneuroim.2004.10.025. PMID: 15710475 
Ullian, EM, Harris, BT, Wu, A, Chan, JR and Barres, BA (2004) Schwann cells and astrocytes induce synapse 
formation by spinal motor neurons in culture. Mol Cell Neurosci 25:241-51. doi: 
10.1016/j.mcn.2003.10.011. PMID: 15019941 
Urnov, FD, Rebar, EJ, Holmes, MC, Zhang, HS and Gregory, PD (2010) Genome editing with engineered zinc 
finger nucleases. Nat Rev Genet 11:636-46. doi: 10.1038/nrg2842. PMID: 20717154 
Verwer, RW, Dubelaar, EJ, Hermens, WT and Swaab, DF (2002) Tissue cultures from adult human 
postmortem subcortical brain areas. J Cell Mol Med 6:429-32. doi: 10.1111/j.1582-
4934.2002.tb00522.x. PMID: 12417060 
Wang, L, Meece, K, Williams, DJ, Lo, KA, Zimmer, M, Heinrich, G, Martin Carli, J, Leduc, CA, Sun, L, Zeltser, 
LM, Freeby, M, Goland, R, Tsang, SH, Wardlaw, SL, Egli, D and Leibel, RL (2015) Differentiation of 
hypothalamic-like neurons from human pluripotent stem cells. J Clin Invest 125:796-808. doi: 
10.1172/JCI79220. PMID: 25555215 
Wang, S, Bates, J, Li, X, Schanz, S, Chandler-Militello, D, Levine, C, Maherali, N, Studer, L, Hochedlinger, K, 
Windrem, M and Goldman, SA (2013) Human iPSC-derived oligodendrocyte progenitor cells can 
myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12:252-64. doi: 
10.1016/j.stem.2012.12.002. PMID: 23395447 
Wang, T, Wei, JJ, Sabatini, DM and Lander, ES (2014) Genetic screens in human cells using the CRISPR-
Cas9 system. Science 343:80-4. doi: 10.1126/science.1246981. PMID: 24336569 
Wang, WY, Pan, L, Su, SC, Quinn, EJ, Sasaki, M, Jimenez, JC, Mackenzie, IR, Huang, EJ and Tsai, LH 
(2013) Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat 
Neurosci 16:1383-91. doi: 10.1038/nn.3514. PMID: 24036913 
Webster, SJ, Bachstetter, AD, Nelson, PT, Schmitt, FA and Van Eldik, LJ (2014) Using mice to model 
Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 
mouse models. Frontiers in genetics 5:88-88. doi: 10.3389/fgene.2014.00088. PMID: 
MEDLINE:24795750 
Weick, JP, Held, DL, Bonadurer, GF, 3rd, Doers, ME, Liu, Y, Maguire, C, Clark, A, Knackert, JA, Molinarolo, 
K, Musser, M, Yao, L, Yin, Y, Lu, J, Zhang, X, Zhang, SC and Bhattacharyya, A (2013) Deficits in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
32 
human trisomy 21 iPSCs and neurons. Proc Natl Acad Sci U S A 110:9962-7. doi: 
10.1073/pnas.1216575110. PMID: 23716668 
Wen, J-Y, Wei, C-Y, Shah, K, Wong, J, Wang, C and Chen, H-SV (2015) Maturation-Based Model of 
Arrhythmogenic Right Ventricular Dysplasia Using Patient-Specific Induced Pluripotent Stem Cells. 
Circulation Journal advpub. doi: 10.1253/circj.CJ-15-0363.  
Wen, Z, Nguyen, HN, Guo, Z, Lalli, MA, Wang, X, Su, Y, Kim, N-S, Yoon, K-J, Shin, J, Zhang, C, Makri, G, 
Nauen, D, Yu, H, Guzman, E, Chiang, C-H, Yoritomo, N, Kaibuchi, K, Zou, J, Christian, KM, Cheng, L, 
Ross, CA, Margolis, RL, Chen, G, Kosik, KS, Song, H and Ming, G-l (2014) Synaptic dysregulation in 
a human iPS cell model of mental disorders. Nature 515:414-8. doi: 10.1038/nature13716. PMID: 
MEDLINE:25132547 
Wilmut, I, Schnieke, AE, McWhir, J, Kind, AJ and Campbell, KH (1997) Viable offspring derived from fetal and 
adult mammalian cells. Nature 385:810-3. doi: 10.1038/385810a0. PMID: 9039911 
Wolozin, B (2012) Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. 
Alzheimers Res Ther 4:3. doi: 10.1186/alzrt101. PMID: 22264400 
Woodruff, G, Young, JE, Martinez, FJ, Buen, F, Gore, A, Kinaga, J, Li, Z, Yuan, SH, Zhang, K and Goldstein, 
LS (2013) The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total 
loss of PS1 function, in isogenic human stem cells. Cell Rep 5:974-85. doi: 
10.1016/j.celrep.2013.10.018. PMID: 24239350 
Woods, YL, Cohen, P, Becker, W, Jakes, R, Goedert, M, Wang, X and Proud, CG (2001) The kinase DYRK 
phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-
associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming 
kinase. Biochem J 355:609-15. PMID: 11311121 
Wren, MC, Zhao, J, Liu, CC, Murray, ME, Atagi, Y, Davis, MD, Fu, Y, Okano, HJ, Ogaki, K, Strongosky, AJ, 
Tacik, P, Rademakers, R, Ross, OA, Dickson, DW, Wszolek, ZK, Kanekiyo, T and Bu, G (2015) 
Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and 
induces cellular stress in iPSC-derived neural stem cells. Mol Neurodegener 10:46. doi: 
10.1186/s13024-015-0042-7. PMID: 26373282 
Wunderlich, P, Glebov, K, Kemmerling, N, Tien, NT, Neumann, H and Walter, J (2013) Sequential proteolytic 
processing of the triggering receptor expressed on myeloid cells-2 (TREM2) by ectodomain shedding 
and gamma-secretase dependent intramembranous cleavage. J Biol Chem. doi: 
10.1074/jbc.M113.517540. PMID: 24078628 
Xie, L, Kang, H, Xu, Q, Chen, MJ, Liao, Y, Thiyagarajan, M, O'Donnell, J, Christensen, DJ, Nicholson, C, Iliff, 
JJ, Takano, T, Deane, R and Nedergaard, M (2013) Sleep drives metabolite clearance from the adult 
brain. Science 342:373-7. doi: 10.1126/science.1241224. PMID: 24136970 
Xu, X, Lei, Y, Luo, J, Wang, J, Zhang, S, Yang, XJ, Sun, M, Nuwaysir, E, Fan, G, Zhao, J, Lei, L and Zhong, Z 
(2013) Prevention of beta-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of 
Cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 10:213-27. doi: 
10.1016/j.scr.2012.11.005. PMID: 23305945 
Yagi, T, Ito, D, Okada, Y, Akamatsu, W, Nihei, Y, Yoshizaki, T, Yamanaka, S, Okano, H and Suzuki, N (2011) 
Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet 20:4530-9. 
doi: 10.1093/hmg/ddr394. PMID: 21900357 
Yahata, N, Asai, M, Kitaoka, S, Takahashi, K, Asaka, I, Hioki, H, Kaneko, T, Maruyama, K, Saido, TC, 
Nakahata, T, Asada, T, Yamanaka, S, Iwata, N and Inoue, H (2011) Anti-Abeta drug screening 
platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One 
6:e25788. doi: 10.1371/journal.pone.0025788. PMID: 21984949 
Yang, F, Sun, X, Beech, W, Teter, B, Wu, S, Sigel, J, Vinters, HV, Frautschy, SA and Cole, GM (1998) 
Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-
associated neurons and microglia in Alzheimer's disease. Am J Pathol 152:379-89. PMID: 9466564 
Yoshida, M, Kitaoka, S, Egawa, N, Yamane, M, Ikeda, R, Tsukita, K, Amano, N, Watanabe, A, Morimoto, M, 
Takahashi, J, Hosoi, H, Nakahata, T, Inoue, H and Saito, MK (2015) Modeling the early phenotype at 
the neuromuscular junction of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Reports 
4:561-8. doi: 10.1016/j.stemcr.2015.02.010. PMID: 25801509 
Yoshimizu, T, Pan, JQ, Mungenast, AE, Madison, JM, Su, S, Ketterman, J, Ongur, D, McPhie, D, Cohen, B, 
Perlis, R and Tsai, LH (2015) Functional implications of a psychiatric risk variant within CACNA1C in 
induced human neurons. Mol Psychiatry 20:284. doi: 10.1038/mp.2014.181. PMID: 25623946 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
33 
Youmans, KL, Tai, LM, Nwabuisi-Heath, E, Jungbauer, L, Kanekiyo, T, Gan, M, Kim, J, Eimer, WA, Estus, S, 
Rebeck, GW, Weeber, EJ, Bu, G, Yu, C and LaDu, MJ (2012) APOE4-specific changes in Aβ 
accumulation in a new transgenic mouse model of alzheimer disease. Journal of Biological Chemistry 
287:41774-41786.  
Young, JE, Boulanger-Weill, J, Williams, DA, Woodruff, G, Buen, F, Revilla, AC, Herrera, C, Israel, MA, Yuan, 
SH, Edland, SD and Goldstein, LS (2015) Elucidating molecular phenotypes caused by the SORL1 
Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 
16:373-85. doi: 10.1016/j.stem.2015.02.004. PMID: 25772071 
Yusa, K, Rashid, ST, Strick-Marchand, H, Varela, I, Liu, PQ, Paschon, DE, Miranda, E, Ordonez, A, Hannan, 
NR, Rouhani, FJ, Darche, S, Alexander, G, Marciniak, SJ, Fusaki, N, Hasegawa, M, Holmes, MC, Di 
Santo, JP, Lomas, DA, Bradley, A and Vallier, L (2011) Targeted gene correction of alpha1-antitrypsin 
deficiency in induced pluripotent stem cells. Nature 478:391-4. doi: 10.1038/nature10424. PMID: 
21993621 
Zeng, H, Guo, M, Martins-Taylor, K, Wang, X, Zhang, Z, Park, JW, Zhan, S, Kronenberg, MS, Lichtler, A, Liu, 
HX, Chen, FP, Yue, L, Li, XJ and Xu, RH (2010) Specification of region-specific neurons including 
forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS One 5:e11853. doi: 
10.1371/journal.pone.0011853. PMID: 20686615 
Zhang, B, Gaiteri, C, Bodea, LG, Wang, Z, McElwee, J, Podtelezhnikov, AA, Zhang, C, Xie, T, Tran, L, 
Dobrin, R, Fluder, E, Clurman, B, Melquist, S, Narayanan, M, Suver, C, Shah, H, Mahajan, M, Gillis, T, 
Mysore, J, MacDonald, ME, Lamb, JR, Bennett, DA, Molony, C, Stone, DJ, Gudnason, V, Myers, AJ, 
Schadt, EE, Neumann, H, Zhu, J and Emilsson, V (2013) Integrated systems approach identifies 
genetic nodes and networks in late-onset Alzheimer's disease. Cell 153:707-20. doi: 
10.1016/j.cell.2013.03.030. PMID: 23622250 
Zhang, D, Pekkanen-Mattila, M, Shahsavani, M, Falk, A, Teixeira, AI and Herland, A (2014) A 3D Alzheimer's 
disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived 
neurons. Biomaterials 35:1420-8. doi: 10.1016/j.biomaterials.2013.11.028. PMID: 24290439 
Zhang, F, Wen, Y and Guo, X (2014) CRISPR/Cas9 for genome editing: progress, implications and 
challenges. Hum Mol Genet 23:R40-6. doi: 10.1093/hmg/ddu125. PMID: 24651067 
Zhang, F, Wang, LP, Boyden, ES and Deisseroth, K (2006) Channelrhodopsin-2 and optical control of 
excitable cells. Nat Methods 3:785-92. doi: nmeth936 [pii] 
10.1038/nmeth936. PMID: 16990810 
Zhang, N, An, MC, Montoro, D and Ellerby, LM (2010) Characterization of Human Huntington's Disease Cell 
Model from Induced Pluripotent Stem Cells. PLoS Curr 2:RRN1193. doi: 10.1371/currents.RRN1193. 
PMID: 21037797 
Zhang, Q, Yu, JT, Zhu, QX, Zhang, W, Wu, ZC, Miao, D and Tan, L (2010) Complement receptor 1 
polymorphisms and risk of late-onset Alzheimer's disease. Brain Res 1348:216-21. doi: 
10.1016/j.brainres.2010.06.018. PMID: 20558149 
Zhang, Y, Chen, K, Sloan, SA, Bennett, ML, Scholze, AR, O'Keeffe, S, Phatnani, HP, Guarnieri, P, Caneda, 
C, Ruderisch, N, Deng, S, Liddelow, SA, Zhang, C, Daneman, R, Maniatis, T, Barres, BA and Wu, JQ 
(2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of 
the cerebral cortex. J Neurosci 34:11929-47. doi: 10.1523/JNEUROSCI.1860-14.2014. PMID: 
25186741 
Zhang, Y, Pak, C, Han, Y, Ahlenius, H, Zhang, Z, Chanda, S, Marro, S, Patzke, C, Acuna, C, Covy, J, Xu, W, 
Yang, N, Danko, T, Chen, L, Wernig, M and Südhof, TC (2013) Rapid Single-Step Induction of 
Functional Neurons from Human Pluripotent Stem Cells. Neuron 78:785-798. doi: 
papers2://publication/doi/10.1016/j.neuron.2013.05.029.  
Zhou, T, Benda, C, Dunzinger, S, Huang, Y, Ho, JC, Yang, J, Wang, Y, Zhang, Y, Zhuang, Q, Li, Y, Bao, X, 
Tse, HF, Grillari, J, Grillari-Voglauer, R, Pei, D and Esteban, MA (2012) Generation of human induced 
pluripotent stem cells from urine samples. Nat Protoc 7:2080-9. doi: 10.1038/nprot.2012.115. PMID: 
23138349 
Zhu, Z, Gonzalez, F and Huangfu, D (2014) The iCRISPR platform for rapid genome editing in human 
pluripotent stem cells. Methods in enzymology 546:215-50. doi: 10.1016/b978-0-12-801185-0.00011-
8. PMID: MEDLINE:25398343 
Zou, J, Maeder, ML, Mali, P, Pruett-Miller, SM, Thibodeau-Beganny, S, Chou, BK, Chen, G, Ye, Z, Park, IH, 
Daley, GQ, Porteus, MH, Joung, JK and Cheng, L (2009) Gene targeting of a disease-related gene in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
34 
human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5:97-110. doi: 
10.1016/j.stem.2009.05.023. PMID: 19540188 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
35 
Table 1. Literature reviewed. 
Reference Lab* 
Ye
ar 
PMID Cell Source 
Dise
ase 
Mutation/G
ene 
Genome 
Editing/Iso
genic lines 
Cell 
Types 
Examined 
Phenotypes Reported 
Drug 
treatment 
Profilin
g 
Yagi et 
al., 2011 
Suz
uki 
201
1 
2190
0357 
iPSCs from 
Coriell hFib: 
AG07768, 
AG09908; Clone 
201B7
1
 
fAD, 
spor
adic 
PD 
PSEN1 
A246E, 
PSEN2 
N141I 
 Neurons Aβ 
Compound 
E, 
Compound 
W 
Gene 
expressi
on 
microarr
ay 
Liu et al., 
2011 
Izpis
ua 
Bel
mon
te 
201
1 
2134
6760 
H9 ESCs; iPSCs 
from BJ hFib, 
Coriell hFib: 
AG01972, 
AG11498, 
AG06297, 
GM00038, 
AG05247,  
AG09602. 
HGP
S 
prog
eria 
LMNA 
G608G 
 
 
Smooth 
muscle 
cells 
Premature senescence, 
nuclear defects  
DNA 
methylat
ion 
microarr
ay 
Israel et 
al., 2012 
Gold
stein 
201
2 
2227
8060 
iPSCs from 
primary patient 
hFibs 
fAD, 
sAD 
APP 
duplication 
 
NPCs, 
neurons 
Aβ, Tau, GSK3β activity, 
Endosomes, Vesicle 
trafficking, Synapse 
formation/ function  
Compound 
E, DAPT 
Gene 
expressi
on 
microarr
ay 
Koch et 
al., 2012 
Walt
er 
201
2 
2251
0327 
ESCs: I3 (TE03); 
iPSCs: PKa
2
 
fAD, 
Overexpress
ion of 
PSEN1 
L166P and 
D385N 
 
lt-NES 
cells, 
NPCs, 
neurons 
Aβ, NPC proliferation 
DAPT, 
ibuprofen 
indometha
cin 
 
Maclean 
et al., 
2012 
Orki
n 
201
2 
2304
5682 
ESCs: CSES2 
and CSES13
3
. 
iPSCs: DS2, DS1 
MRC5-IPS7
4
 
DS Trisomy 21 
Spontaneo
us disomic 
isogenic 
lines 
Hematopo
ietic cells 
Aβ, hematopoiesis 
 
 
Shi et al., 
2012 
Live
sey 
201
2 
2234
4463 
ESCs: DS-ES 
SC-321, H9; 
iPSCs: DS1-
iPS4
4
 
DS Trisomy 21  
NPCs, 
neurons 
Aβ, aggregates, Tau DAPT  
Kondo et 
al., 2013 
Inou
e 
201
3 
2343
4393 
iPSCs from 
primary patient 
hFibs 
fAD, 
sAD 
APP E693Δ 
and V717L 
 
Neurons, 
astrocytes 
Aβ, Cellular/oxidative 
stress,  
DHA, 
DBM14-
26, 
NSC23766
,  BACE 
inhibitor IV 
(BSI) 
Gene 
expressi
on 
microarr
ay 
Fong et 
al., 2013 
Hua
ng 
201
3 
2431
9659 
iPSCs from 
primary patient 
hFibs 
FTD 
MAPT 
A152T 
Zinc finger 
nucleases 
NPCs, 
Tau, Neural degeneration, 
Dopaminergic phenotypes   
 
Xu et al., 
2013 
Zho
ng 
201
3 
2330
5945 
ESCs: H9, iPSCs: 
hiPS-C4 line. iCell 
Neurons. 
AD 
Exogenous 
Aβ 
 
NPCs, 
neurons 
Neuronal viability, Cell 
cycle, Neurogenesis, 
Differentiation 
Cdk 
inhibitors 
Compou
nd 
screen 
Weick et 
al., 2013 
Bhat
tach
aryy
a 
201
3 
2371
6668 
iPSCs from 
Coriell hFib: 
AG05397, 
GM02504. 
DS Trisomy 21 
Disomic 
isogenic 
cells via 
mosaicism 
NPCs, 
neurons 
Cellular/oxidative stress, 
Synapse formation/ 
function 
 
Gene 
expressi
on 
microarr
ay 
Miller et 
al., 2013 
Stud
er 
201
3 
2431
5443 
iPSCs from 
Coriell hFib: 
AG06917, 
AG06297, 
AG11498 
HGP
S 
Prog
eria, 
PD 
LMNA 
C1824T; 
PINK1 
Q456X; 
Parkin 
V324A. 
 Neurons 
Cellular/oxidative stress, 
Cellular aging, Lewy-body-
precursor-like inclusions, 
DNA damage, 
Mitochondrial dysfunction 
 
RNA-
Seq 
Choi et 
al., 2014 
Kim 
201
4 
2530
7057 
ReN cell VM 
human neural 
stem (ReN) 
cells (Millipore) 
fAD 
Overexpress
ion of APP 
K670N/ 
M671L/V717
I; 
PSEN1(ΔE9
 
3D neural 
culture in 
Matrigel 
Aβ, Tau, Neural 
degeneration 
Compound 
E, BACE 
inhibitor IV 
(BSI), 
DAPT, 
SGSM41 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
36 
) 
Hibaoui 
et al., 
2014 
Feki 
201
4 
2437
5627 
iPSCs from 
primary patient 
hFibs 
DS Trisomy 21 
Isogenic 
cells from 
discordant 
monozygoti
c twins 
NPCs, 
neurons, 
neurosphe
res 
Synapse number, NPC 
Viability, DYRK1A activity, 
Neurogenesis, 
Differentiation 
epigallocat
echine 
gallate 
(EGCG) 
RNA-
Seq 
Muratore 
et al., 
2014 
You
ng-
Pear
se 
201
4 
2452
4897 
iPSCs: hFibs from 
HSCI 
fAD APP V717I  
iPSCs, 
NPCs, 
Neurons 
Aβ, Tau, APP cleavage, 
Endosomes 
DAPT, 
Compound 
E, BACE 
inhibitor 
C3, Anti-
Aβ 
antibodies 
Nanostri
ng gene 
expressi
on array 
Sproul et 
al., 2014 
Nog
gle 
201
4 
2441
6243 
iPSCs: hFibs from 
Coriell AG07671, 
AG07768, 
AG08446 
fAD 
PSEN1 
A246E, 
M146L 
 
iPSCs, 
NPCs, 
neurons 
Aβ, differentiation 
Recombin
ant Norrin 
 
Gene 
expressi
on 
microarr
ay 
Wren et 
al., 2015 
Bu 
201
5 
2637
3282 
iPSCs from 
primary patient 
hFibs 
FTD 
MAPT 
N279K 
 NPCs 
Tau, Endosomes, Vesicle 
trafficking, 
Cellular/oxidative stress 
 
 
Iovino et 
al., 2015 
Spill
antin
i 
201
5 
2622
0942 
iPSCs from 
primary patient 
hFibs, Coriell 
hFib: ND32854, 
ND40076 
FTD 
MAPT 
N279K, 
P301L 
 Neurons 
Tau, Mitochondrial 
dysfunction, α synuclein, 
Neurogenesis, 
Differentiation 
 
RNA-
Seq 
Young et 
al., 2015 
Gold
stein 
201
5 
2577
2071 
hFibs from UCSD 
ADRC, J.C.V. 
sAD 
SORL1 
SNPs 
 
NPCs, 
neurons 
Aβ, SORL1 induction 
 
 
Murray 
et al., 
2015 
Nize
tic 
201
5 
2569
4335 
Young adult hFibs 
from Galliera 
Genetic Bank 
DS 
 
Disomic 
isogenic 
cells via 
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Frontotemporal Dementia. DS = Down syndrome.  NPCs = neural progenitor cells. HSCI = Harvard Stem Cell Institute. 
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